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subarachnoid hemorrhage (sAH) is a relevant 
health problem and a significant cause of morbidity 
and mortality throughout the world. The annual in-
cidence of aneurysmal sAH (asAH), which varies 
widely among populations, perhaps because of genetic 
differences, competing burden of disease and issues of 
case ascertainment, is generally accepted to be 9.1 per 
100 000 per year worldwide1. because death resulting 
from asAH often occurs before hospital admission, 
the true incidence of asAH might be even higher2. 
The data also show that the incidence of asAH in-
creases with age, with a typical average age at onset 
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in adults ≥50 years1,3, increases as children get older1,4, 
is higher in women than in men5, with a higher inci-
dence reported in younger men (24-45 years of age), 
in women between 55 and 85 years and men >85 years 
of age, and also differs according to race and ethnic-
ity6,7. 
The prognosis of asAH is influenced by mul-
tiple non-modifiable factors and by factors that can 
be influenced by therapeutic interventions and man-
agement procedures. The most reliable data on the 
natural history of ruptured saccular intracranial an-
eurysms are obtained from the study by pakarinen 
et al.8. Cumulative case fatality rates over time after 
asAH are as follows: day 1: 25%-30%; week 1: 40%-
45%; first month: 50%-60%; sixth month: 55%-60%; 
year 1: 65%; and year 5 after sAH: 65%-70%. it is 
estimated that approximately 12% of patients die be-
fore reaching medical attention9. if those patients who 
die before medical attention are included, 43% of all 
sAH patients die without recovering from the initial 
bleeding; of those, 74% die within the first 24 hours, 
7% within 2-3 days, 12% within 4-7 days, 5% within 
week 2, 1% within week 3, and 1% later than 3 weeks 
after the initial sAH8. if a ruptured aneurysm is left 
untreated, about one-third of patients who recover 
from the initial hemorrhage die because of recurrent 
bleeding within 6 months after sAH10. The cumula-
tive risk of rebleeding by 6 months after sAH is 50%, 
the annual risk of rebleeding decreases to 3% during 
the next 10 years, while in two-thirds of these late, 
recurrent bleedings cause death11-13. despite improve-
ments in surgical and medical treatment, rupture of 
an aneurysm is still associated with high rates of case 
fatality (roughly one-third) and severe disability (one-
sixth)14,15. However, between 1973 and 2002, the case 
fatality rate decreased by approximately 17%16 and 
the possibility to recover an independent state has in-
creased by 1.5% per year14. Case fatality and functional 
outcome after sAH are determined by the severity of 
the initial bleeding14,17, age17,18, aneurysm site18 and 
size17,18, history of hypertension17,18, high systolic blood 
pressure17, heavy alcohol consumption19 and cigarette 
smoking, that has also been reported to increase the 
risk of delayed cerebral ischemia (dCi)20. 
After aneurysm rupture, the possibility of poor 
outcome rises and is probably determined by multi-
ple independent factors including disease-associated 
events, treatment-associated factors and complica-
tions associated with prolonged bed rest. As described 
above, asAH can have devastating effects on the cen-
tral nervous system as well as a profound impact on 
several other organs. The course of the disease can be 
prolonged and additionally complicated by systemic 
manifestations affecting cardiovascular, pulmonary 
and renal function. due to profound effects of the 
hemorrhage itself and accompanying complications, 
asAH patients are routinely admitted to an intensive 
care unit (iCu) and are cared for by a multidisci-
plinary team including neurologists-neurointensivists, 
neurosurgeons, anesthesiologists and interventional 
neuroradiologists. The iCu course of asAH patients 
ranges from a few days to a few weeks and is frequent-
ly accompanied by multiple medical complications21, 
including the following: hydrocephalus, rebleeding, 
delayed cerebral ischemia from vasospasm, seizures, 
cardiopulmonary complications and hyponatremia. 
There have been few guidelines published for asAH 
management22-24, emphasizing mostly risk factors, 
prevention, natural history and prevention of rebleed-
ing, and recommendations discussing the critical care 
issues involved in the care of asAH patients21. since 
the complex multiorgan pathophysiology of asAH 
presents a multitude of clinical challenges which de-
mand attention21, the purpose of these Recommenda-
tions is to offer an overview and practice guidelines for 
the management of medical complications in patients 
following asAH, being responsible for the outcome 
and health-related quality of life in patients after 
asAH. Recommendations are in accordance with the 
Recommendations of the neurocritical Care society’s 
multidisciplinary Consensus Conference21, guide-
lines for the management of Aneurysmal subarach-
noid Hemorrhage for Healthcare professionals of the 
American Heart Association/American stroke Asso-
ciation22, and european stroke organization guide-
lines for the management of intracranial Aneurysms 
and subarachnoid Hemorrhage23. Recommendations 
have been developed based on the literature, evalua-
tion of the results of large international randomized 
controlled trials and the collective experience of the 
authors. These Recommendations have been assessed 
and endorsed by the Croatian society of neurovascu-
lar disorders, Croatian society of neurology – sec-
tion of neurocritical Care, Croatian society of neu-
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rosurgery, and Croatian society for difficult Airway 
management.
These Recommendations are assessing the compli-
cations of asAH. because of the multiplicity of dif-
ferent complications and low incidence of each, not 
being high enough to conduct a prospective clinical 
trial, the superiority of certain procedure over the 
other was not possible to assess. most of the compli-
cations are managed according to the expert opinion. 
Therefore, the grading of Recommendations Assess-
ment, development and evaluation (gRAde) sys-
tem was preferred for the evaluation of evidence and 
recommended treatment. 
As specified, the quality of the data was assessed 
and recommendations have been developed using the 
gRAde system25. The quality of evidence was grad-
ed as:
•	 High	=	Further	research	is	very	unlikely	to	change	
our confidence in the estimate effects.
•	 Moderate	=	Further	 research	 is	 likely	 to	have	an	
important impact on our confidence in the esti-
mate of effect and may change the estimate.
•	 Low	=	Further	 research	 is	 very	 likely	 to	have	an	
important impact on our confidence in the esti-
mate of effect and is likely to change the estimate.
•	 Very	 low	=	Any	 estimate	 of	 effect	 is	 very	 uncer-
tain.
The gRAde system classifies recommendations 
as strong or weak, according to the balance among 
benefits, risks, burden and cost, and the quality of 
evidence. An advantage of gRAde system is that it 
allows for strong recommendations in the setting of 
lower quality evidence and thus it is well suited to this 
situation25. Recommendations were either strong or 
weak and based primarily on the quality of evidence 
and translation of the evidence into practice in a spe-
cific setting.
Hydrocephalus
Aneurysmal sAH can cause hydrocephalus, de-
fined as a bicaudate index on the computed tomog-
raphy (Ct) scan exceeding the 95th percentile for age, 
by two mechanisms: obstruction of cerebrospinal fluid 
(Csf) pathways (i.e. acute, obstructive, noncommu-
nicating type) and blockage of arachnoid granulations 
by scarring (i.e. chronic, delayed, nonobstructive, 
communicating type)26. Acute hydrocephalus occurs 
in 15% to 87% of patients with asAH27,28. Chronic 
shunt-dependent hydrocephalus occurs in 8.9% to 
48% of patients with asAH29-31. 
Acute hydrocephalus may be caused by obstruction 
of the Csf circulation pathways by interfering with 
Csf outflow through the sylvian aqueduct, fourth 
ventricular outlet, basal cisterns and subarachnoid 
space. Csf production and absorption rates are unal-
tered32. intraventricular blood is the strongest deter-
minant for the development of acute hydrocephalus. 
other risk factors include bilateral ambient cisternal 
blood, increased age, vasospasm, use of antifibrin-
olytic drugs, left ventricular systolic dysfunction, sub-
dural hematoma and seizures33. Acute hydrocephalus 
associated with sAH is usually managed by external 
ventricular drainage or lumbar drainage. external 
ventricular drainage for patients with asAH is gen-
erally associated with neurological improvement34. 
About one-third of patients with acute hydrocephalus 
are asymptomatic and half of the patients with ini-
tial hydrocephalus and impairment of consciousness 
improve spontaneously within 24 hours35. patients 
with acute hydrocephalus may be in poor neurological 
condition immediately after asAH and have dilated 
ventricles on Ct scan. such acute hydrocephalus is 
related to the amount of intraventricular hemorrhage 
rather than aneurysmal bleeding itself36. some neuro-
surgeons prefer not to use ventricular drain in these 
patients immediately, as half of them will improve 
spontaneously and there is a risk of rebleeding and in-
fection. The risk of aneurysm rebleeding with external 
ventricular drainage has been studied in 3 retrospec-
tive case series, and the risk of rebleeding was found 
to be high in one study37, whereas the other 2 studies 
found no increased risk38,39. Although ventriculosto-
my increases the risk of rebleeding and meningitis/
ventriculitis40, the recommended approach is to start 
immediate external ventricular drainage keeping in-
tracranial pressure between 10 and 20 mm Hg in all 
of these patients, if there is no other obvious expla-
nation for a reduced level of consciousness, such as 
massive intracerebral hemorrhage (iCH)41. lumbar 
drainage as a consecutive treatment of external ven-
tricular drainage before shunting for the treatment 
of asAH associated hydrocephalus has been reported 
to be safe in terms of no increase in the risk of re-
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bleeding, particularly in patients with spontaneous 
iCH when the third and fourth ventricles are free of 
blood, i.e. communicating hydrocephalus. This ap-
proach may be considered as an alternative approach 
to reduce the frequency of permanent shunts, but it 
is important to pay attention to downward hernia-
tion in case of supratentorial swelling and the devel-
opment of hygroma42,43. The theoretical risk of tissue 
shift after placement of lumbar drain in patients with 
severe intracranial hypertension should be considered 
when deciding which method of cerebrospinal fluid 
diversion to use, particularly in patients with associ-
ated intraparenchymal hematomas. when obstructive 
hydrocephalus is suspected, an external ventricular 
drainage should be preferred. furthermore, prelimi-
nary data have also suggested that lumbar drainage is 
associated with a reduced incidence of vasospasm44,45. 
serial lumbar punctures to manage acute asAH as-
sociated hydrocephalus have also been described as 
safe, but this strategy has only been assessed in small 
retrospective series38,46. 
only a proportion of patients with asAH associ-
ated acute hydrocephalus develop shunt-dependent 
chronic hydrocephalus. A number of retrospective 
series have attempted to identify factors predictive 
of its development29,30,47,48. A meta-analysis of 5 non-
randomized studies with 1718 pooled patients (1336 
having undergone clipping and 382 having undergone 
coiling) found a lower risk of shunt dependency in the 
clipping group (relative risk 0.74; 95% confidence in-
terval, 0.58-0.94) than in the coiling group (p<0.01)48. 
However, only 1 out of 5 studies showed an indepen-
dent significant difference49. Three other nonrandom-
ized series not included in the meta-analysis showed 
no significant difference between clipping and coil-
ing in shunt-dependent chronic hydrocephalus31,50,51. 
fenestration of lamina terminalis has been suggested 
to reduce the incidence of shunt-dependent chronic 
hydrocephalus, yet a meta-analysis of 11 randomized 
studies with 1973 pooled patients found no signifi-
cant difference between patients who had and had not 
undergone fenestration of the lamina terminalis52. A 
nonrandomized study not included in the meta-analy-
sis and not reporting statistical significance compared 
95 patients who had undergone aneurysmal clipping, 
cisternal blood evacuation and lamina terminalis fen-
estration with 28 comparable, non-blood-cleansed, 
endovascular therapy-treated patients and found that 
shunt-dependent hydrocephalus occurred in 17% of 
surgical patients versus 33% of patients treated with 
endovascular therapy50.
Recommendations for the management of 
hydrocephalus associated with aSAH 
•	 Aneurysmal	 SAH-associated	 acute	 symptomatic	
hydrocephalus should be managed by cerebrospi-
nal fluid diversion (external ventricular drainage 
or lumbar drainage, depending on the clinical sce-
nario) (moderate Quality evidence; strong Rec-
ommendation).
•	 Aneurysmal	 SAH-associated	 chronic	 symptom-
atic hydrocephalus should be treated with perma-
nent cerebrospinal fluid diversion (low Quality of 
evidence; strong Recommendation).
•	 Weaning	 external	 ventricular	 drainage	 over	 >24	
hours does not appear to be effective in reduc-
ing the need for ventricular shunting (moderate 
Quality of evidence; weak Recommendation).
•	 Routine	fenestration	of	the	lamina	terminalis	is	not	
useful for reducing the rate of shunt-dependent hy-
drocephalus and therefore should not be routinely 
performed (moderate Quality of evidence; weak 
Recommendation).
Rebleeding
Rebleeding following asAH is a common event 
and is associated with very high mortality and poor 
prognosis for functional recovery in survivors. The 
risk of rebleeding is maximal in the first 2 to 12 
hours, more than one-third of rebleeds occur within 
3 hours, and nearly half within 6 hours of symptom 
onset53, with reported rates of occurrence between 4% 
and 13.6% within the first 24 hours (that is, during 
transportation or before the treatment team is able 
to occlude the aneurysm)54, and 5%-10% in the first 
72 hours55. early rebleeding is associated with worse 
outcome than later rebleeding56. patients surviving 
the first day after the initial asAH have a cumulative 
risk of 35%-40% to suffer rebleeding of the aneurysm, 
with a mortality rate of about 40%. After 4 weeks, 
the risk of rebleeding decreases to about 3%/year57. 
factors associated with aneurysm rebleeding include 
longer time to aneurysm treatment, worse neurologi-
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cal status on admission, initial loss of consciousness, 
previous sentinel headaches, larger aneurysm size and 
possible systolic blood pressure >160 mm Hg58-60. ge-
netic factors, although related to the occurrence of in-
tracranial aneurysms, do not appear to be related to an 
increased incidence of rebleeding61. 
The primary goal of the treatment of aneurysmal 
sAH is immediate repair of the ruptured aneurysm, 
in order to close the bleeding source and prevent re-
bleeding. some patients either have too high Hunt 
and Hess scale (HHs) score for immediate repair or 
require transport to a center where repair can be per-
formed by experienced team, in order to minimize the 
serious procedural side effects of repair. Those facts 
can lead to further delay in repair and increased risk 
of rebleeding. Among the patients who present in a 
delayed manner and during the vasospasm window, 
delayed obliteration of aneurysm is associated with 
a higher risk of rebleeding62. Three interventions are 
considered that might modulate the risk of rebleed-
ing: blood pressure control, antifibrinolytic therapy, 
and catheter versus Ct. 
Blood pressure control 
There is a general agreement that acute hyperten-
sion should be controlled after asAH and until aneu-
rysm obliteration, but parameters for blood pressure 
control have not been defined and there are no sys-
tematic data that address blood pressure levels in pa-
tients with unsecured aneurysms in relation to the risk 
of rebleeding. data from observational studies sug-
gest that aggressive treatment of blood pressure may 
decrease the risk of rebleeding, but at the cost of an 
increased risk of secondary ischemia63. Recent series 
do not report rebleeding at systolic blood pressure in 
the range of 160-200 mm Hg63. it seems reasonable, 
but without good evidence, to stop any antihyper-
tensive medication that the patients were using and 
not to treat hypertension unless the blood pressure is 
extreme. it is not possible to give limits for ‘extreme’ 
blood pressure because it differs in different patients 
according to their age, previous blood pressure, car-
diac history, and other factors and limits should be 
set on an individual basis. The clear consensus is that 
modest blood pressure elevation (mean arterial pres-
sure <110 mm Hg; systolic blood pressure <160 mm 
Hg) is not associated with rebleeding and does not re-
quire therapy; extreme hypertension, i.e. if the systolic 
blood pressure exceeds 180 mm Hg, in patients with 
an unsecured, recently ruptured aneurysm, should 
be treated aiming to a modest (e.g., 25%) decrease 
in the mean arterial pressure; pre-morbid baseline 
blood pressures should be used to refine targets and 
hypotension should be avoided21. 
A variety of titratable medications are available. 
nicardipine may give smoother blood pressure control 
than labetalol64 and sodium-nitroprusside65, although 
data showing different clinical outcomes are lacking. 
Although lowering cerebral perfusion pressure may 
lead to cerebral ischemia63, a cohort study of neuro-
logically critically ill patients did not find an associa-
tion between the use of nicardipine and reduced brain 
oxygen tension66. to conclude, between the time of 
asAH symptom onset and aneurysm obliteration, 
blood pressure should be controlled with a titratable 
agent to balance the risk of stroke, hypertension-relat-
ed rebleeding, and maintenance of cerebral perfusion 
pressure. 
Antifibrinolytic therapy
because of the increased risk of intracranial bleed-
ing from thromboprophylaxis by means of low-molec-
ular weight heparins, more often intracranial bleeding 
complications and no overall influence on outcome or 
appearance of post-asAH cerebral infarction67,68, the 
use of stockings and/or pneumatic devices seems more 
appropriate in asAH patients before occlusion of the 
aneurysm23. in case that deep vein thrombosis pre-
vention is indicated, low-molecular-weight heparin 
should be applied not earlier than 12 h after surgical 
occlusion of the aneurysm and immediately after coil-
ing23. 
Antifibrinolytic therapy has been shown to reduce 
the incidence of aneurysm rebleeding when there is a 
delay in aneurysm obliteration. in a Cochrane review 
including 9 randomized trials of antifibrinolytic drugs 
in asAH, antifibrinolytic treatment reduced the risk 
of rebleeding but did not influence death from all 
causes or a poor outcome69. one referral center insti-
tuted a policy of short-term use of aminocaproic acid 
to prevent rebleeding during patient transfer. it led to 
a decreased incidence of rebleeding, without increas-
ing the risk of delayed cerebral ischemia and increased 
risk of deep venous thrombosis but no pulmonary em-
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bolism, with no effect on 3-month clinical outcomes70. 
A swedish trial tested a strategy where tranexamic 
acid was given as soon as asAH had been diagnosed 
in the local hospital (before the patients were trans-
ported) and continued until aneurysm occlusion, 
which was typically performed within 72 hours. it 
showed again the overall outcome that did not ap-
preciably improve in patients treated with tranexamic 
acid, despite an impressive reduction in rebleeding71. 
if this trial is pooled with the 9 other trials included in 
the Cochrane review, there is still no effect on overall 
outcome72. 
Antifibrinolytic therapy is relatively contraindi-
cated in patients with risk factors for thromboembolic 
complications (moderate Quality evidence; strong 
Recommendation) and consequently, patients treated 
with antifibrinolytic therapy should have close screen-
ing for deep venous thrombosis (moderate Quality 
evidence; strong Recommendation)21. for patients 
with an unavoidable delay in obliteration of aneu-
rysm, a significant risk of rebleeding and no compel-
ling medication contraindications, short term (<72 
hours) therapy with tranexamic acid or aminocaproic 
acid to reduce the risk of early aneurysm rebleeding is 
reasonable22 (moderate Quality evidence; moderate 
Recommendation). in accordance with the above, an 
early, short course of antifibrinolytic therapy prior to 
early aneurysm repair (begun at diagnosis, continued 
up to the point at which the aneurysm is secured or at 
72 hours post-ictus, whichever is shorter) should be 
considered21 (low Quality evidence; weak Recom-
mendation). furthermore, delayed (>48 hours after 
the ictus) or prolonged (>3 days) antifibrinolytic ther-
apy exposes patients to side effects of therapy when 
the risk of rebleeding is sharply reduced and should 
be avoided21 (High Quality evidence; strong Recom-
mendation) and it should be discontinued 2 hours be-
fore planned endovascular ablation of the aneurysm21 
(Very low Quality evidence; weak Recommenda-
tion). 
neither aminocaproic acid nor tranexamic acid is 
approved by the united states food and drug Ad-
ministration (us fdA) or by european medical 
Agency (emA) for the use in european union, for 
prevention of aneurysm rebleeding22. There is cur-
rently no medical treatment that improves outcome 
by reducing rebleeding23 (High Quality evidence; 
strong Recommendation). Although theoretically re-
combinant factor Viia might prevent rebleeding, at 
this moment there is no evidence to support the use 
of recombinant factor Viia outside study protocols in 
patients with asAH23. further definitive evidence of 
benefit from antifibrinolytic agents will require addi-
tional trials before this therapy can be implemented in 
clinical practice. 
Catheter versus CT angiography
several individual case reports or case series with 
poorly defined total number of patients have reported 
aneurysmal rebleeding with rates as high as 20%-
38.5% when digital subtraction angiography (dsA) 
is undertaken very early (less than 3-6 hours) follow-
ing asAH73-76. The results showed that the figures 
were much lower (~5%) where a clear denominator 
was provided to assess the incidence of rebleeding74; 
furthermore, it is unclear whether these instances of 
rebleeding with dsA actually reflect the risk of the 
procedure or are simply a manifestation of the high 
rebleeding rates, known to occur after initial aneu-
rysm rupture; and, finally, there is no satisfactory di-
rect comparison of rebleeding with and without dsA 
or Ct angiography (CtA) within the first 6 hours 
post asAH21. given all the above, as well as the fact 
that CtA is now well established and it seems un-
likely that a large study comparing dsA and CtA 
will ever materialize, it seems unreasonable to con-
clude that this is a specific risk attributed to ultra early 
dsA. based on epidemiological data, choosing CtA 
over dsA for ultra-early angiography is a reasonable 
option where both options are available, the technical 
quality of CtA is good, and an endovascular inter-
vention is not planned at the time of angiography21. 
However, there is no case for delaying investigation, 
either CtA or dsA, in the setting of asAH, where 
the overwhelming aim is to detect and secure a culprit 
aneurysm21.
Recommendations for medical measures to prevent 
rebleeding after aSAH
•	 Early	aneurysm	repair	should	be	undertaken,	when	
possible and reasonable, to prevent rebleeding21 
(High Quality evidence; strong Recommenda-
tion). 
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•	 If	possible,	it	should	be	aimed	to	intervene	at	least	
within 72 hours after onset of first symptoms23 
(High Quality evidence; strong Recommenda-
tion). 
•	 This	 decision	 should	 depend	 on	 grading	 since,	
according to our experience, patients with worse 
clinical presentation (HH iV and V) should be 
individually evaluated and treated as soon as they 
become medically stable. otherwise, the risk of 
treatment outweighs the risk of rerupture. 
•	 Between	 the	 time	 of	 aSAH	 symptom	onset	 and	
aneurysm obliteration, blood pressure should be 
controlled with a titratable agent to balance the 
risk of stroke, hypertension-related rebleeding and 
maintenance of cerebral perfusion pressure22 (High 
Quality evidence; strong Recommendation). 
•	 The	magnitude	of	blood	pressure	control	to	reduce	
the risk of rebleeding has not been established, but 
a decrease in systolic blood pressure to <160 mm 
Hg is reasonable (moderate Quality evidence; 
strong Recommendation).
•	 Modest	 elevation	 in	 blood	 pressure	 (mean	 blood	
pressure <110 mm Hg) does not require therapy. 
pre-morbid baseline blood pressures should be 
used to refine targets; hypotension should be 
avoided21 (low Quality evidence; strong Recom-
mendation).
•	 An	 early,	 short	 course	 of	 antifibrinolytic	 therapy	
prior to early aneurysm repair (begun at diagnosis; 
continued up to the point at which the aneurysm 
is secured or at 72 hours post-ictus, whichever is 
shorter) should be considered21 (low Quality of 
evidence; weak Recommendation).
•	 Delayed	(>48	hours	after	the	ictus)	or	prolonged	(>3	
days) antifibrinolytic therapy exposes patients to 
side effects of therapy when the risk of rebleeding 
is sharply reduced and should be avoided21 (High 
Quality evidence; strong Recommendation). 
•	 Antifibrinolytic	therapy	is	relatively	contraindicat-
ed in patients with risk factors for thromboembo-
lic complications21 (moderate Quality evidence; 
strong Recommendation). 
•	 Patients	treated	with	antifibrinolytic	therapy	should	
have close screening for deep venous thrombosis21 
(moderate Quality evidence; strong Recommen-
dation). 
•	 When	CTA	and	DSA	are	both	available	and	CTA	
is of high technical quality, CtA should be per-
formed preferentially if endovascular intervention 
is not planned at the time of angiography21 (Very 
low Quality evidence; weak Recommendation). 
•	 There	is	currently	no	medical	antifibrinolytic	treat-
ment that improves outcome by reducing rebleed-
ing23 (High Quality evidence; strong Recommen-
dation). 
Delayed Cerebral Ischemia from Vasospasm
delayed cerebral ischemia from vasospasm is one 
of the most common causes of death, disability and 
delayed neurological deterioration following asAH76. 
notwithstanding, the definitions used to describe 
vasospasm and dCi are numerous and not standard-
ized, which makes it difficult to compare results be-
tween treatment or intervention trials, and interferes 
with the development of evidence based guidelines. 
one of the major contributors to this problem is the 
inappropriate tendency to combine radiographic evi-
dence of vascular narrowing and clinical findings into 
a single definition. it is a general agreement that in-
consistencies in the use of the terms vasospasm and 
dCi should be avoided and that standardized defini-
tions are needed21. 
Vasospasm is a term applied to arterial narrow-
ing after sAH demonstrated by radiographic images 
or sonography. it is generally accepted that it should 
only be used as a term describing the findings on di-
agnostic studies. it is believed to be induced in the 
areas of thick subarachnoid clot78. The putative agent 
responsible for vasospasm is oxyhemoglobin, but its 
true etiology and pathogenesis remain to be elucidat-
ed79. According to current knowledge, the cascade of 
events culminating in arterial narrowing is initiated 
when oxyhemoglobin comes in contact with the al-
buminal side of the vessel events80. most often, the 
terminal internal carotid artery or the proximal por-
tions of the anterior and middle cerebral arteries are 
involved. The arterial territory involved, however, is 
not related to the location of the ruptured aneurysm81. 
while changes in vasospasm are commonly observed 
in the large caliber conveyance arteries, effects on the 
smaller vessels of the microcirculation, including al-
terations in blood brain barrier permeability, may be 
equally important in determining clinical impact. 
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such factors may account for the higher incidence 
of vasospasm as defined by imaging criteria (‘radio-
graphic vasospasm’) than the rates of neurological 
dysfunction (‘clinical vasospasm’)82. Vasospasm can 
result in decreased cerebral blood flow and oxygen de-
livery, which may produce dCi, a term applied to any 
neurological deterioration (e.g., hemiparesis, apha-
sia, altered consciousness) presumed to be related to 
ischemia, which persists for more than an hour and 
cannot be explained by other physical abnormalities 
noted on standard radiographic, electrophysiological 
or laboratory findings78. neurological deterioration in 
the context of sAH encompasses clinically detectable 
neurological deterioration in a sAH patient following 
initial stabilization, but excludes further sAH due to 
new bleeding from the ruptured aneurysm. it is also 
generally agreed that “clinical deterioration due to 
dCi” should only be used to describe a clinical find-
ing78. dCi may occur but neurological deterioration 
may not be recognized due to poor clinical condi-
tion of the patient and/or administration of sedatives. 
furthermore, although dCi and vasospasm are of-
ten used as surrogate markers of each other and they 
can both be associated with clinical deterioration and 
worse outcomes, either one may also be asymptomatic 
and they can also occur independently21. since recent 
studies provided evidence that cerebral infarction 
on neuroimaging had the strongest association with 
functional outcomes83-85, it has been recommended re-
cently by a multidisciplinary research group that sAH 
clinical trials should only use cerebral infarction and 
functional outcome as the primary outcome measures, 
whereas clinical deterioration due to dCi and vasos-
pasm on angiography or tCd should only be second-
ary outcome measures21. 
Monitoring strategies for delayed neurological 
deterioration, delayed cerebral ischemia and 
vasospasm 
Knowing that dCi is one of the most common 
causes of delayed neurological deterioration and the 
major cause of secondary morbidity that is potentially 
treatable and reversible, early detection of impaired 
cerebral perfusion and early intervention to detect and 
reverse ischemia before the occurrence of permanent 
infarction is the goal of monitoring for dCi after 
asAH. furthermore, it is considered a high-priority 
topic because the choice of monitoring strongly influ-
ences the specific triggers used for further hemody-
namic or endovascular intervention to treat vasospasm 
and dCi. The highest risk period for dCi occurs 3-14 
days after asAH and higher risk patients are those 
with larger amounts of sAH and poorer clinical 
grade21. 
monitoring strategies and tools for dCi in sAH 
are divided into three basic categories: clinical, radio-
graphic and physiological21, the last two being com-
monly used to identify arterial narrowing and per-
fusion abnormalities or reduced brain oxygenation. 
These different tools have advantages and disadvan-
tages. 
Clinical monitoring for dCi consists of repeated 
neurological assessments to identify new neurological 
deficits that are attributable to ischemia or infarction. 
two studies found that Ct scans identified asymp-
tomatic infarction in 10%-20% of patients with clini-
cally unrecognized infarcts, more common in patients 
in coma86,87. A study using magnetic resonance imag-
ing (mRi) found clinically unrecognized infarcts in 
23% of patients88. The results of the studies clearly 
showed that not all ischemic events are detected on 
clinical examinations and it is generally thought that 
the utility of clinical examination in detecting revers-
ible ischemia is good in good-grade patients and less 
reliable in poor-grade patients who are obtunded or 
comatose. notwithstanding, there is a strong consen-
sus that clinical examination is an important first as-
sessment point in patients with asAH; that triggers 
for further monitoring and intervention may differ 
depending on the clinical status of the patient; and 
that clinical examination alone is an insufficient mon-
itoring paradigm for detection of dCi, especially in 
poor-grade patients21. furthermore, there is a general 
consensus that additional radiographic and/or physi-
ological monitoring should be routinely employed in 
the monitoring of asAH patients for dCi and should 
be performed during the dCi at risk period, even in 
the absence of clinical evidence of dCi or prior to its 
occurrence21.
Radiographic monitoring modalities include con-
ventional digital subtraction angiography (dsA), Ct 
(Ct angiography, CtA and Ct perfusion imaging, 
Ctp) and mRi. dsA is considered gold standard 
for detection of arterial narrowing and thus is a com-
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monly used radiographic method to define vasospasm, 
with a limitation of not being able to assess the ad-
equacy of perfusion to meet metabolic demands of 
the tissue. on the other hand, CtA is found to be 
highly correlated with dsA findings of large artery 
narrowing, 87%-95% specific for angiographic vasos-
pasm compared with dsA and with high specificity 
and negative predictive value (npV) of 95%-99%, 
suggesting that it could be used as a screening tool 
to limit the use of dsA, but at the same time tends 
to overestimate the degree of stenosis89,90. Ctp does 
provide some measure of tissue perfusion, which may 
enhance the predictive value of multi-modality Ct for 
dCi monitoring. its finding of delayed mean transit 
time >6.4 s in conjunction with arterial narrowing on 
CtA is found to be more accurate in predicting the 
need of endovascular intervention for vasospasm91,92, 
but it does not currently evaluate the posterior fossa 
well. Considering mRi as a possible dCi monitor-
ing tool at this time, it would require further trials for 
adequate and satisfactory data. overall, according to 
radiographic monitoring strategy for dCi in asAH, 
concerning the emerging concerns regarding radia-
tion toxicity, an institutional protocol that balances 
dCi detection with attempts to minimize radiation 
exposure is encouraged.
physiological monitoring modalities are the third 
basic category among the monitoring strategies and 
tools for dCi in asAH, which include transcranial 
doppler ultrasonography (tCd), electroencephalog-
raphy (eeg), brain tissue oxygen monitoring, cere-
bral microdialysis, thermal diffusion cerebral blood 
flow (td-Cbf) monitoring and near-infrared spec-
troscopy. 
transcranial doppler ultrasonography has long 
been used for monitoring patients with asAH and 
has been more extensively studied in comparison with 
dsA. Although studies of tCd diagnostic accuracy 
for detection of vasospasm and dCi vary widely with 
regard to sensitivity and specificity93,94, it is generally 
considered that tCd has a fairly high specificity but 
only moderate sensitivity compared with dsA93,94. 
differentiation of elevated tCd velocities secondary 
to vasospasm versus other causes in monitoring pa-
tients with asAH is crucial. it can be accomplished 
by measuring velocities in the cervical internal carotid 
artery (iCA) in addition to the intracerebral vessels, 
creating ratios for clinical use that aim to overcome 
the confounding effects of systemic hemodynamic 
factors, such as changes in cardiac output or blood 
pressure. tCd velocities have been used to create 
several clinically relevant predictive indices, including 
the lindegaard ratio (ratio of middle cerebral artery 
(mCA) tCd velocity to ipsilateral internal carotid 
artery (iCA) tCd velocity), that is especially use-
ful for vasospasm diagnosis. A VmCA/ViCA ratio >3 is 
suggestive of cerebral vasospasm95. A similar velocity 
ratio profile between the basilar and extracranial ver-
tebral arteries can be used to assess for basilar vasos-
pasm96. A 2001 meta-analysis reported that, for mCA 
vasospasm, overall tCd specificity was 99% and sen-
sitivity 67%, with a positive predictive value (ppV) of 
97% and npV of 78%. for the anterior cerebral artery 
(ACA), iCA, posterior circulation and examinations 
of the distal cerebral microvasculature, tCd values 
were significantly less sensitive and specific97. A con-
sensus statement in 2004 underscored these results, 
supporting the conclusion that tCd is a reliable pre-
dictor for the absence of angiographic vasospasm (high 
npV) at flow velocities <120 cm/s and for the pres-
ence of angiographic vasospasm (high ppV) at flow 
velocities >200 cm/s in the mCA territory. According 
to the mentioned consensus, flow velocities below 120 
cm/s (absence), >200 cm/s (presence), mCA/iCA ra-
tio >6 (presence) or rapidly increasing velocities over 
several days (high risk) are commonly considered 
thresholds94,98. Velocity measurements between 120 
cm/s and 200 cm/s may require further technical ma-
neuvers (manual carotid compression)99 or additional 
clinical information to improve diagnostic accuracy. 
moreover, intermediate tCd values generally do 
not reliably correlate with angiographic vasospasm100. 
Clinically, trends in tCd values or interval changes 
from prior readings are often more informative than 
absolute values82. daily monitoring of changes in 
tCd values can speak in favor of development of va-
sospasm100. Therefore, tCd on days 2-5 can detect 
the development of vasospasm days before it can be-
come clinically apparent, and this information can 
be used by intensivists to step up with hemodynamic 
management of these patients. on days 5-12, tCd 
can detect progression to the severe phase of spasm 
when development of the delayed ischemic deficit due 
to perfusion failure through the residual lumen is the 
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greatest. This information can help planning inter-
ventions (angiography, nicardipine infusion). on days 
12 to the end of iCu stay, tCd can document spasm 
resolution after treatment or intervention, sustainabil-
ity of vessel potency, and infrequent cases of late or 
rebound vasospasm development at the end of the sec-
ond or into the third week after asAH. in conclusion, 
due to the absence of radiation risk, relatively low cost 
and ease/rapidity of bedside administration, tCd 
measurements are practical for serially monitoring the 
progression of cerebral vasospasm. The technique is 
limited by the lack of high-resolution anatomic de-
tail, and its accuracy and utility are highly operator-
dependent and patient movement-dependent. in ad-
dition, aberrant vessel course, aneurysm clip artifacts 
and suboptimal insonation windows can inhibit the 
detection of pathological velocities82,101. 
brain tissue oxygen (pbto2) monitoring and ce-
rebral microdialysis (Cmd) are directly measuring 
tissue oxygen delivery and metabolism, providing, 
rather than direct correlation, information comple-
mentary to that from radiographic studies. Their 
role in measuring these physiological parameters in 
monitoring patients with asAH has been described in 
several observational studies102,103. However, no stud-
ies examined the effectiveness of interventions based 
on these monitoring tools in preventing or reversing 
dCi. Regarding the role of eeg in monitoring pa-
tients with sAH, findings of reduced alpha variability 
have been indicative of dCi, but no interventional 
trials examined eeg-directed dCi treatment104. Al-
together, eeg, pbto2 monitoring and Cmd may all 
be useful physiological monitors for dCi detection, 
but the relative value of these monitors individually 
versus as part of a multi-modality monitoring strategy 
is not known (low Quality evidence; weak Recom-
mendation)21.
to conclude, there is a strong consensus that clini-
cal examination is an important first assessment point 
in patients with asAH, while triggers for further 
monitoring and intervention may differ depending on 
the clinical status of the patient. furthermore, there 
is also great concern that clinical examination alone 
was an insufficient monitoring paradigm for detection 
of dCi, especially in poor-grade patients, leading to a 
consensus that additional radiographic and/or physi-
ological monitoring should be routinely employed in 
the monitoring of asAH patients, performed during 
the dCi at risk time period, even in the absence of 
clinical evidence of dCi or prior to its occurrence21. 
based on the past knowledge and clinical experience, 
the following can be recommended: 
a) low Risk good-grade asAH patients – the pri-
mary monitoring tool is repeated clinical evalua-
tion, supplemented by monitoring with regular 
daily tCd. in case of the development of a new 
focal deficit, a change in the level of conscious-
ness not clearly attributable to another cause, or 
an increase in tCd velocities/lindegaard ratio 
should prompt additional investigations (CtA or 
dsA) that seek to detect or monitor the evolution 
of arterial narrowing and document the presence 
of perfusion deficits (Ctp) that results from such 
narrowing. where the selected investigation can-
not be obtained emergently, within 1-2 hours, de-
pending on the clinical situation, medical therapy 
for dCi should be initiated while awaiting imag-
ing21. 
b) good-grade sAH patients at High Risk of Va-
sospasm and/or dCi – patients with a high fisher 
grade and/or arterial narrowing demonstrated with 
dsA/CtA at the time of initial presentation may 
benefit from monitoring with these techniques in 
the absence of detectable clinical consequences. 
The development of new deficits and/or changes 
in sensorium will often directly trigger therapeutic 
interventions. in case of substantial clinical un-
certainty whether the change in clinical status is 
actually due to dCi; an endovascular intervention 
is being considered; and/or the risks of therapy are 
particularly high (e.g., blood pressure elevation in a 
patient with significant ischemic heart disease), re-
peating CtA+Ctp should be performed. Regard-
ing the radiation burden and renal impairment, in 
case of screening for vasospasm or dCi the risk/
benefit ratio is considered more favorable21.
c) sedated or poor-grade sAH patients – clinical 
examination may be less useful as a monitoring 
tool in this setting but should still be regularly un-
dertaken, since a change from baseline provides an 
indication for further investigation or treatment. 
A clinical suspicion of vasospasm or dCi in these 
sAH patients will be triggered by a change in 
tCd parameters, eeg, invasive cerebral moni-
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toring, or by the detection of vasospasm or per-
fusion deficits on routine screening CtA/Ctp 
or dsA. where the clinical suspicion of dCi is 
based on a non-imaging tool, it is prudent to con-
firm the diagnosis using CtA+Ctp or dsA. it 
is reasonable to initiate therapy without further 
investigation in patients where screening using 
CtA or dsA has already established vasospasm 
and the clinical picture is consistent and in poor-
grade patients where a perfusion deficit has been 
demonstrated on screening Ctp, unless the deficit 
coincides with an established infarction21.
Considering thresholds for cessation of therapy 
for dCi, in good-grade patients clinical assessment 
combined with cautious staged de-escalation of 
therapy provides the best basis for management deci-
sions, whereas in poor-grade patients, this approach 
may need to be supplemented by investigations that 
include tCd trends of vasospasm, continuous eeg 
monitoring, pbto2, and/or microdialysis. in case 
when dCi has resulted in established infarction, it 
may be appropriate to withdraw therapy because it has 
been unsuccessful. it is important to emphasize that it 
is unwise to base treatment decisions (initiation, titra-
tion or withdrawal) on an individual measurement 
provided by any single monitoring modality or moni-
toring device (technical artifact, inter-center variabil-
ity), especially knowing that while some physiological 
thresholds may be associated with outcome, there is no 
clear evidence that correction of the monitored vari-
able actually improves outcome. it is prudent to inte-
grate data from all available sources with the clinical 
picture to help make management decisions. in case 
of the development of new neurological deficit with a 
strong likelihood of being due to ischemia and other 
potential causes were unlikely or had been excluded, 
most centers would initiate therapy. The threshold 
values from tCd and other monitoring devices pro-
vide additional information that underpins initiation 
of therapy. some therapies, including hypertension 
and optimization of hemoglobin levels, may be ini-
tiated while awaiting confirmatory investigations. 
on the other hand, other interventions used in dCi, 
such as endovascular therapy, require angiography for 
initiation and in these instances confirmation of the 
diagnosis of vasospasm as a cause of dCi will auto-
matically precede therapy21. because of all the above 
mentioned challenges in monitoring asAH patients, 
there is, however, a strong consensus that monitoring 
for neurological deterioration and specifically dCi 
should take place in an environment with substan-
tial multidisciplinary expertise in the management 
of asAH (hospital and intensive care unit), with ad-
equate expertise to implement and interpret monitor-
ing tools, where additional monitoring and treatment 
can be rapidly implemented when needed21,105 (Very 
low Quality evidence; strong recommendation).
Management of Cerebral Vasospasm and DCI 
after aSAH
Although the pathways leading to arterial nar-
rowing have been in focus of extensive basic research, 
no effective preventive therapy has been developed to 
date. probably, the reason for this stems in part from 
the fact that the vasospasm occurs at multiple levels in 
the arterial and arteriolar circulation. it is known that 
large artery narrowing seen in angiographically visible 
vessels only results in ischemic neurological symptoms 
in 50% of patients. Although there is a correlation be-
tween the severity of large artery spasm and symp-
tomatic ischemia, there are patients with severe large 
artery spasm who never become symptomatic and 
other with modest spasm who not only develop symp-
toms but go on to develop infarction78. probably many 
factors contribute to the development of ischemia and 
infarction, including but not limited to distal micro-
circulatory failure, poor collateral anatomy, and ge-
netic or physiological variations in cellular ischemic 
tolerance106,107. 
The management of asAH-induced vasospasm is 
complex. Currently, the strongest evidence supports 
the use of prophylactic oral nimodipine and mainte-
nance of euvolemia and initiation of hemodynamic 
augmentation therapy (triple-H therapy) for patients 
with cerebral vasospasm and/or endovascular therapy 
with vasodilators and angioplasty balloons108.
As for nimodipine, the results of a recent compre-
hensive meta-analysis have confirmed improved neu-
rological outcomes by preventing processes other than 
large-vessels narrowing and should be administered 
to all patients with asAH (High Quality evidence; 
strong Recommendation)109. it should be noted that 
nimodipine has been shown to improve neurologi-
cal outcomes by decreasing the incidence of cere-
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bral ischemia110, but not cerebral vasospasm. it has 
been postulated that the nimodipine beneficial role 
may be the result of a more complex neuroprotective 
mechanism of action than that of its vasodilatory ef-
fect111. Although the risk reduction for ‘poor outcome’ 
is statistically robust, it depends mainly on a single 
large trial112 and therefore the benefits of nimodipine 
cannot be regarded as being beyond all reasonable 
doubt23. The practical implication is that the regimen 
in the dominant nimodipine trial (60 mg orally every 
4 h for 3 weeks) is currently regarded as the standard 
treatment in patients with asAH. if the patient is 
unable to swallow, the nimodipine tablets should be 
coarse-grained crushed and washed down a nasogas-
tric tube with normal saline within minutes23. intra-
venous administration of calcium antagonists is ad-
vocated by the manufacturer, but besides the fact that 
it is more expensive, there is no evidence to support 
this and cannot be recommended for routine practice 
on the basis of current evidence113. The value of other 
calcium antagonists, whether administered orally or 
intravenously, remains uncertain22. 
with regard to blood volume, maintenance of eu-
volemia and normal circulating blood volume is rec-
ommended to prevent dCi (High Quality evidence; 
strong Recommendation)21. when dCi is diagnosed, 
the initial treatment is the induction of hemodynamic 
augmentation to improve cerebral perfusion. tradi-
tionally, hemodynamic augmentation has consisted of 
hemodilution, hypervolemia and hypertensive thera-
py (triple-H therapy). Although no randomized trial 
of this intervention has been performed, the rapid 
improvement of many patients with this therapy and 
their worsening when it is stopped prematurely are a 
convincing proof of efficacy. The exact mechanism of 
benefit is unclear22. in some patients, increased mean 
arterial pressures may increase cerebral blood flow in 
the setting of autoregulatory dysfunction, whereas in 
others, there may be some direct transluminal pres-
sure effect that leads to arterial dilation110. However, 
the existent literature provides only level b evidence 
regarding the utilization of triple-H therapy in the 
management of patients suffering from asAH114. Re-
cently, macdonald et al. have reported their experi-
ence from employing continuous milrinone infusion 
instead of triple-H therapy. They found that milri-
none regimen required less invasive monitoring and 
resources than triple-H therapy, while its hemody-
namic effect was comparable to that of the triple-H 
therapy115. further large-scale clinical trials are nec-
essary for validating their observations. Accumulat-
ing literature has shifted the focus from this triple-H 
therapy to the maintenance of euvolemia and induced 
hypertension116. induction of hypertension is recom-
mended for dCi unless blood pressure is elevated at 
baseline or cardiac status precludes it23 (High Quality 
evidence; strong Recommendation). The data show 
that both prophylactic angioplasty of the basal cere-
bral arteries and antiplatelet prophylaxis are ineffec-
tive in reducing morbidity117-119. Consequently, pro-
phylactic hypervolemia or balloon angioplasty before 
the development of angiographic spasm is not recom-
mended23 (moderate Quality evidence; strong Rec-
ommendation); cerebral angioplasty and/or selective 
intra-arterial vasodilator therapy is reasonable in pa-
tients with symptomatic cerebral vasospasm, particu-
larly those who are not rapidly responding to hyper-
tensive therapy (moderate Quality evidence; strong 
recommendation)22. 
with regard to the value of the lumbar drain-
age after SAH, the data from one case-control study 
showed a markedly reduced risk of clinically evident 
vasospasm and its sequels, shortened hospital stay and 
improved outcome. The beneficial effect is probably 
mediated through the removal of spasmogens that ex-
ist in the Csf, but a randomized clinical trial is war-
ranted and ongoing phase iii trial has been designed 
to test its influence on outcome120. The data from a 
meta-analysis of 5 randomized, controlled trials sug-
gested a benefit from intrathecal thrombolytic infu-
sions following asAH but further standardization of 
techniques and evaluation in a larger, more rigorous 
randomized controlled trial is required121. The effect 
of intraventricular fibrinolysis on clinical outcome and 
mortality of asAH patients is currently being investi-
gated in a large-scale phase iii clinical trial122. 
The administration of the endothelin-1 antagonist, 
clazosentan, has been shown to be associated with a 
dose-dependent reduction in the incidence of angio-
graphic vasospasm in a phase ii b trial123, but proven 
to cause no significant improvement in the clinical 
outcome of patients with asAH116. 
significant interest has been arisen by the em-
ployment of magnesium as a vasodilatory agent for 
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preventing and/or reversing cerebral vasospasm. Cer-
tainly, the use of magnesium has potential benefits in 
the setting of asAH, with the minimal risk of severe 
adverse or side effects such as hypotension, hypocalce-
mia or bradycardia. magnesium reduced the frequency 
of dCi in a dose-dependant fashion124. Results of the 
mash-2 (magnesium for Aneurysmal subarachnoid 
Hemorrhage) trial revealed that treatment with mag-
nesium did not improve outcome and was not supe-
rior to placebo in reducing poor outcome in sAH pa-
tients125. The potential role of magnesium in relieving 
persistent sAH-associated headache needs to be ex-
plored in the future. based on the currently published 
data, the systemic administration of magnesium can-
not be generally recommended. magnesium sulfate is 
a promising agent but more evidence is needed before 
definitive conclusions can be drawn126. 
in regard to the employment of statins in the 
management of vasospasm, the currently available 
data have shown that in the majority of cases there 
is a definite vasodilatory effect on the cerebral vas-
culature127-131. Results of the stAsH (simvastatin 
in Aneurysmal subarachnoid Hemorrhage) trial are 
expected to clarify the exact effect of statins on the 
clinical outcome of patients with asAH. 
it has been postulated that other pathophysiologi-
cal mechanisms than vasospasm may contribute to 
post-asAH morbidity and mortality. inflammatory 
mechanisms, endothelial apoptosis, cortical spread-
ing depolarization, microthrombosis and lipid per-
oxidation have been implicated in the pathogenesis 
of delayed ischemic events132-135. other agents with 
a potential benefit in preventing and/or treating 
post-asAH vasospasm and dCi include nitric oxide 
promoters, free radical scavengers, thromboxane in-
hibitors, thrombolysis, anti-inflammatory agents and 
neuroprotectants. Although promising data begin to 
emerge for several treatments, few prospective ran-
domized clinical trials are presently available. Addi-
tionally, future investigational efforts will need to re-
solve discrepant definitions and outcome measures for 
cerebral vasospasm in order to permit adequate study 
comparisons. until then, definitive recommendations 
cannot be made regarding the safety and efficacy of 
each of these therapeutic strategies and medical man-
agement practices will continue to be implemented in 
a wide-ranging manner108. 
Recommendations for prevention of delayed ischemic 
deficit 
•	 monitoring for neurological deterioration and 
specifically dCi should take place in an environ-
ment with substantial multidisciplinary expertise 
in the management of asAH21 (moderate Qual-
ity evidence; strong Recommendation). patients 
at a high risk of dCi should be closely monitored 
throughout the at risk period, which is best accom-
plished in an iCu setting where additional moni-
toring and treatment can be rapidly implemented21 
(Very low Quality evidence; strong Recommen-
dation). 
•	 Nimodipine	 should	 be	 administered	 orally	 (60	
mg/4 h) to all patients with asAH for a period 
of 21 days to prevent delayed ischemic events21-23 
(High Quality evidence; strong Recommenda-
tion).
•	 Maintenance	of	euvolemia	and	normal	circulating	
blood volume is recommended to prevent delayed 
cerebral ischemia22 (moderate Quality evidence; 
strong Recommendation).
•	 Prophylactic	hypervolemia	or	balloon	angioplasty	
before the development of angiographic spasm is 
not recommended22 (moderate Quality evidence; 
strong Recommendation). 
•	 Imaging	of	vascular	anatomy	and/or	perfusion	can	
be used to confirm the diagnosis of dCi in moni-
tored good-grade patients who show a change 
in neurological examination or tCd variables21 
(High Quality evidence; strong Recommenda-
tion).
•	 A	strategy	for	detection	and	confirmation	of	DCI	
should be employed. This should first and foremost 
involve frequent repeat neurological assessment by 
qualified providers. intermittent screening or more 
continuous monitoring methods may additionally 
be used21.
•	 TCD	is	reasonable	to	monitor	for	the	development	
of arterial vasospasm (moderate Quality evidence; 
strong Recommendation)21-23. Thresholds of mean 
blood flow velocities <120 cm/s for absence and 
>200 cm/s and/or mCA/iCA ratio >6 for pres-
ence are reasonable21 (moderate Quality evidence; 
strong Recommendation).
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•	 DSA	is	gold	standard	for	detection of large artery 
vasospasm21 (High Quality evidence; strong Rec-
ommendation).
•	 High	quality	CTA	can	be	used	on	 screening	 for	
vasospasm and due to its high specificity may re-
duce the need of dsA studies21 (low Quality evi-
dence; weak Recommendation)21.
•	 Perfusion	imaging	with	CT	or	MRI	can	be	use-
ful to identify regions of potential brain ischemia22 
(moderate Quality evidence; strong Recommen-
dation).
•	 In	 high	 risk	 patients	who	have	 a	 clinical	 picture	
strongly suggestive of dCi and in whom elective 
screening CtA or dsA has already demonstrated 
vasospasm/dCi, it is reasonable to initiate medical 
therapy without further investigation21 (moderate 
Quality evidence; strong Recommendation).
•	 In	patients	with	clinical	uncertainty	regarding	the	
cause of neurological deterioration, dsA is indi-
cated if an endovascular intervention is planned21 
(moderate Quality evidence; strong Recommen-
dation).
•	 In	sedated	or	poor-grade	patients,	clinical	deterio-
ration may be difficult to assess, and tCd, contin-
uous eeg, pbto2 monitoring and/or Cmd are 
options for monitoring for vasospasm and dCi21 
(low Quality evidence; weak Recommenda-
tion).
•	 Induction	of	hypertension	is	recommended	for	pa-
tients with dCi unless blood pressure is elevated 
at baseline or cardiac status precludes it22 (moder-
ate Quality evidence; strong Recommendation).
•	 The	choice	of	vasopressor	should	be	based	on	other	
pharmacological properties of the agents21 (e.g., in-
otropy, tachycardia) (moderate Quality evidence; 
strong Recommendation).
•	 Blood	 pressure	 augmentation	 should	 progress	 in	
a stepwise fashion with assessment of neurologi-
cal function at each mean arterial pressure (mAp) 
level to determine if a higher blood pressure target 
is appropriate21 (poor Quality evidence; strong 
Recommendation).
•	 If	nimodipine	administration	 results	 in	hypoten-
sion, then dosing intervals should be changed to 
more frequent lower doses. if hypotension contin-
ues to occur, then nimodipine may be discontin-
ued21 (low Quality evidence; strong Recommen-
dation).
•	 If	patients	with	DCI	do	not	 improve	with	blood	
pressure augmentation, a trial of inotropic thera-
py may be considered21 (low Quality evidence; 
strong Recommendation). inotropes with promi-
nent β-2 agonist properties (e.g., dobutamine) may 
lower mAp and require increases in vasopressor 
dosage21 (High Quality evidence; strong Recom-
mendation).
•	 Cerebral	angioplasty	and/or	selective	intra-arterial	
vasodilator therapy is reasonable in patients with 
symptomatic cerebral vasospasm, particularly 
those who are not rapidly responding to hyperten-
sive therapy22 (moderate Quality evidence; strong 
Recommendation).
•	 Hemodilution	 in	 an	 attempt	 to	 improve	 rheol-
ogy should not be undertaken except for cases of 
erythrocythemia21 (moderate Quality evidence; 
strong Recommendation).
•	 If	 the	aneurysm	thought	 to	have	 ruptured	 is	un-
secured when the patient develops dCi, cautious 
blood pressure elevation to improve perfusion 
might be attempted, weighing the potential risks 
and benefits21 (weak Quality evidence; strong 
Recommendation).
•	 Unsecured	 aneurysms	 which	 are	 not	 thought	 to	
be responsible for the acute sAH should not in-
fluence hemodynamic management21 (moderate 
Quality evidence; strong Recommendation).
•	 Magnesium	 sulfate	 is	 not	 recommended	 for	 the	




Retrospective studies have identified several risk 
factors for the development of early seizures associ-
ated with asAH, including aneurysm in the mCA136, 
thickness of a asAH clot137, associated intracerebral 
hematoma138-140, rebleeding137, infarction141, poor neu-
rological grade137, history of hypertension142 and sur-
gical aneurysm repair in patients >65 years of age137. 
Abnormal movements that may appear seizure-like 
Acta Clin Croat,  Vol. 53,   No. 1,  2014 127
Vesna Vargek solter et. al. Recommendations for the management of post-asAH complications
are common at the onset of asAH (as many as 26%) 
but it is usually unclear whether this is a true sei-
zure or represents posturing at the time of aneurysm 
rupture138,143. The incidence, future implications and 
management of seizures associated with asAH are 
controversial. Clinical seizures are uncommon after 
the initial aneurysm rupture, occurring in 1%-7% of 
patients, and when they occur in patients with an un-
secured aneurysm, they are often the manifestation of 
aneurysmal re-rupture144,145. At present, no random-
ized, controlled trials are available to guide decisions 
on prophylaxis or treatment of seizures. The mode of 
treatment for patients with ruptured aneurysms also 
appears to influence the subsequent development of 
seizures22. Results of the studies have demonstrated 
that patients treated by endovascular coiling showed 
a significantly lower incidence of seizures144,146. Al-
though high-quality evidence for routine anticonvul-
sant use in asAH patients without seizures is lacking, 
short-term prophylactic antiepileptic therapy is still 
commonly used in patients with asAH137,143, based on 
the argument that seizures in acutely ill patients with 
asAH could lead to additional injury or rebleeding 
from an unsecured aneurysm. Recent studies have sug-
gested that prophylactic anticonvulsant therapy with 
phenytoin may worsen outcome147, whereas the im-
pact of other anticonvulsant medication is less clear148. 
Also, in patients with no history of seizure, a short 
course (72 h) of anticonvulsant prophylaxis seems as 
effective as a more prolonged course in preventing sei-
zures149. on the other hand, the results from one large 
single-institution study in which anticonvulsants were 
used routinely showed adverse drug effects in 23% of 
patients137, whereas another single-center retrospec-
tive study found the use of prophylactic phenytoin to 
be independently associated with worse cognitive out-
come at 3 months after asAH147. furthermore, data 
pooled from the trials of the impact of other therapies 
also suggest worse outcome in those treated with an-
ticonvulsants. The use of anticonvulsants was also as-
sociated with vasospasm, dCi and fever, which sug-
gests that there may have been a bias in those who 
were treated with antiepileptic drugs148. likewise, al-
though hampered by limitations such as a small num-
ber of patients and anticonvulsant levels not routinely 
monitored, retrospective studies failed to demonstrate 
benefit from the use of prophylactic anticonvulsant 
after asAH150,151. inclusive, it is recommended that 
any purported benefit of routine anticonvulsant use 
in asAH must be tempered by a consideration of the 
potential risks of use22. However, in case of a certain 
subgroup of patients, such as elderly patients under-
going craniotomy that have a higher seizure risk, a 
short course (3-7 days) of anticonvulsant prophylaxis 
might still be considered in some situations, espe-
cially if an agent other than phenytoin is used21,152. 
There is also agreement that patients who suffer clear 
clinical seizure after the period of aneurysmal rup-
ture should be treated with anticonvulsants, but that 
if seizures do not recur, these anticonvulsants should 
be discontinued after 3-6 months. Contrary, there is 
no agreement whether an eeg should be performed 
at that time and, if so, whether seizure-free patients 
with an epileptic focus should be continued on anti-
convulsants21. 
The association between seizures and functional 
outcome still remains unclear. some studies have re-
ported no impact on outcome137,143, whereas others 
found seizures to be independently associated with 
worse outcome153. nonconvulsive status epilepticus 
has been found to be a strong predictor of a poor 
outcome154,155. Concerning the treatment of noncon-
vulsive seizures that may be detected on continuous 
eeg in 10%-20% of comatose asAH patients that are 
proved to have worse outcome, the impact of success-
ful treatment as well as the influence of anticonvul-
sant prophylaxis on the occurrence of nonconvulsive 
seizures have not been studied. There is a consensus 
that continuous eeg is underutilized in poor-grade 
asAH patients, but it is not clear whether noncon-
vulsive seizures represent a marker of disease severity 
or a target for treatment. There is general agreement 
that one or perhaps two anticonvulsants should be 
used to attempt to treat nonconvulsive seizures iden-
tified on continuous eeg, but there is disagreement 
whether or not to pursue more aggressive means such 
as benzodiazepine or barbiturate infusions if initial 
measures were unsuccessful21. 
Recommendations for medical management of 
seizures associated with aSAH
•	 There is no evidence that supports the prophylactic 
use of antiepileptic drugs (Very low Quality evi-
dence; weak Recommendation).
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•	 Antiepileptic	treatment should be administered in 
patients with clinically apparent seizures23.
•	 In	patients	who	suffer	a	seizure	after	presentation,	
anticonvulsants should be introduced and discon-
tinued after two-year seizure-free period, as de-
fined by local practice21 (low Quality evidence; 
weak Recommendation).
•	 Continuous	EEG	monitoring	should	be	consid-
ered in patients with poor-grade asAH who fail 
to improve or who have neurological deteriora-
tion of undetermined etiology; in patients who 
presented with seizure as the initial symptom of 
sAH; in patients with a prolonged post-ictal dis-
turbance of consciousness; and in patients with 
suspicion of nonconvulsive status epilepticus21 
(low Quality evidence; strong Recommenda-
tion). 
•	 The	routine	long-term	use	of	anticonvulsants	is	not	
recommended (moderate Quality evidence; weak 
Recommendation), but may be considered for pa-
tients with known risk factors for delayed seizure 
disorder, such as prior seizure, intracerebral hema-
toma, intractable hypertension, infarction or aneu-
rysm at the middle cerebral artery, and for patients 
with severe epileptiform changes as shown during 
control eeg monitoring22 (moderate Quality ev-
idence; weak Recommendation).
Cardiopulmonary Complications
Cardiac dysfunction occurs in a significant num-
ber of asAH patients. neurogenic sympathetic hy-
peractivity, as well as increased levels of systemic 
catecholamines, has been implicated in asAH-asso-
ciated cardiac dysfunction. Cardiac dysfunction after 
asAH is often referred to as ‘neurogenic stress car-
diomyopathy’156 and has been attributed to the clini-
cal syndrome of chest pain, dyspnea, hypoxemia and 
cardiogenic shock with pulmonary edema and elevat-
ed cardiac markers occurring within hours of sAH. 
This syndrome has a wide spectrum of severity and 
it may contribute to sudden death in 12% of patients. 
The manifestations are usually transient, lasting for 
1-3 days, after which myocardial function returns to 
normal. The management should be focused on sup-
portive care that balances cardiac needs with the neu-
rological goals157.
Arrhythmias occur in as many as 90% of patients 
and are most prevalent in the first 48 hours following 
asAH. They most commonly include premature ven-
tricular complexes, bradyarrhythmias and supraven-
tricular tachycardia. serious cardiac arrhythmias, 
most often atrial fibrillation or flutter, have been de-
scribed in approximately 5% of patients158. Clinically 
significant arrhythmias after aSAH are associated 
with a high mortality rate and serious cardiac and 
neurological comorbidity159. 
electrocardiographic changes occur during the 
acute stage in 50% to 100% of asAH patients160,161. 
The most common abnormalities are nonspecific st 
deviations, t-wave inversion and prolonged Qt in-
terval. These eCg changes have no clinical or prog-
nostic consequence. elevated troponin is found in 
approximately 20% of asAH cases and is associated 
with an increased risk of hypotension, pulmonary 
edema, left ventricular dysfunction and dCi162-164. 
patients with an abnormal eCg on admission should 
undergo close cardiac monitoring. The presence of 
rhythm disturbances should prompt aggressive mea-
sures to treat myocardial infarction, maintain normal 
cardiac rhythm, and minimize the presence of auto-
nomic stress159. The cardiac injury that is found in up 
to 15% of asAH patients is probably caused by the 
massive release of catecholamines165. 
transient left ventricular dysfunction with an 
akinetic or dyskinetic apex has also been described 
in asAH patients without significant coronary heart 
disease166,167. This phenomenon known as Takotsubo 
cardiomyopathy or transient left ventricular apical bal-
looning168 is caused by severe physical (e.g., sAH) 
or emotional stress. more than 95% of patients that 
experienced this stress-induced cardiomyopathy are 
female169. plasma catecholamine concentrations in 
these patients are remarkably higher than in patients 
presenting with myocardial infarction. A possible ex-
planation of this cardiomyopathy is ischemia caused 
by coronary spasm169. 
symptomatic pulmonary complications that 
are associated with worse clinical grade asAH and 
higher mortality occur in over 20% of patients after 
asAH170,171. Aneurysmal sAH patients may develop 
cardiac or neurogenic pulmonary edema172, acute lung 
injury or acute respiratory distress syndrome. The ex-
cessive release of catecholamines (epinephrine/nor-
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epinephrine) or cardiac failure has been suggested as 
the principal cause of pulmonary complications172,173. 
it is also suggested that patients who experience pul-
monary complications after asAH have a higher in-
cidence of symptomatic vasospasm than do patients 
without pulmonary complications. This most likely 
reflects a failure to maintain aggressive hypervolemic 
and hyperdynamic therapy in patients with compro-
mised pulmonary function, as well as the possible pre-
cipitation of congestive heart failure by hypervolemic 
therapy in patients with preexisting delayed ischemic 
neurological deficit174. 
pulmonary complications challenge medical 
management of patients who have sustained asAH. 
Cardiopulmonary issues are worsened in the event of 
hypervolemia, thus the goal of therapy should be eu-
volemia. in general, cardiopulmonary abnormalities 
are more common in patients who later develop dCi 
and have worse outcomes175. They frequently compli-
cate management by increasing procedural risk and 
exarcerbate brain oxygen delivery by lowering perfu-
sion pressure and arterial oxygenation saturation. The 
management of these complications is heterogeneous, 
may vary based on the patient’s clinical status, and in 
the setting of vasospasm and interventions should re-
flect current best medical practice21.
Recommendations for monitoring and medical 
treatment of cardiopulmonary complications in 
aSAH patients
•	 Baseline	 cardiac	 assessment	with	 serial	 enzymes,	
electrocardiography and echocardiography is rec-
ommended, especially in patients with evidence 
for myocardial dysfunction21 (low Quality evi-
dence; strong Recommendation). 
•	 Monitoring	of	cardiac	output	may	be	useful	in	pa-
tients with evidence of hemodynamic instability or 
myocardial infarction21 (low Quality evidence; 
strong Recommendation).
•	 In	 case	of	pulmonary	 edema	or	 evidence	of	 lung	
injury, the goal of therapy should include avoiding 
excessive fluid intake and judicious use of diuret-
ics targeting euvolemia21 (moderate Quality evi-
dence; strong Recommendation).
•	 Standard	management	of	heart	failure	is	indicated	
with the exception that cerebral perfusion pres-
sure/mean arterial pressure (Cpp/mAp) should 
be maintained as appropriate for the neurological 
condition21 (moderate Quality evidence; strong 
Recommendation).
•	 Vigilant	 fluid	 balance	 management	 should	 be	
the foundation for monitoring intravascular vol-
ume status. while both noninvasive and invasive 
monitoring technologies are available, no specific 
modality can be recommended over clinical as-
sessment21,23 (moderate Quality evidence; weak 
Recommendation). 
•	 Central	 venous	 lines	 should	 not	 be	 placed	 solely	
to obtain central venous pressure (CVp) measures 
and fluid management based solely on CVp mea-
surements is not recommended21 (moderate Qual-
ity evidence; strong Recommendation).
•	 Intravascular	 volume	 management	 should	 target	
euvolemia and avoid prophylactic hypervolemic 
therapy. in contrast, there is evidence for harm 
from aggressive administration of fluid aimed at 
achieving hypervolemia21 (High Quality evi-
dence; strong Recommendation)21.
•	 Isotonic	crystalloid	is	the	preferred	agent	for	vol-
ume replacement21,23 (moderate Quality evidence; 
weak Recommendation).
•	 In	patients	with	a	persistent	negative	fluid	balance,	
use of fludrocortisone or hydrocortisone may be 
considered21 (moderate Quality evidence; weak 
Recommendation).
Hyponatremia
Hyponatremia following asAH is the most com-
mon electrolyte imbalance and has prevalence rates 
of approximately 30%-55%176-178. elevated levels of 
atrial natriuretic factor (Anf) and syndrome of inap-
propriate secretion of antidiuretic hormone (siAdH) 
have been implicated. whether caused by siAdH 
or cerebral salt waste syndrome (Csw), hypona-
tremia in patients with asAH has a clear association 
with increased morbidity, including cerebrovascular 
spasm176,179. more recent work emphasizes that the 
diagnosis of Csw requires hypovolemia, whereas 
siAdH usually results in euvolemia or modest hy-
pervolemia180-184. it appears that in asAH, both en-
tities may coexist in the same patient being mani-
fested by excessive urine output with simultaneous 
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excessive free water retention180,181. generally the 
trigger used for treatment is a sodium concentration 
of <135 meq/l or if neurological deterioration is at-
tributed to falling sodium concentration21. Accord-
ing to recently published results of a retrospective, 
single-institution study, the etiology and treatment of 
hyponatremia vary in the presence of hypervolemia/
euvolemia or hypovolemia. while treating these pa-
tients, differentiating between siAdH and Csw is 
essential185. Controlled studies have been performed 
on the use of the corticosteroids fludrocortisone186,187 
and hydrocortisone188,189 to prevent hyponatremia. 
both corticosteroids were consistently effective in 
limiting excessive natriuresis and hyponatremia when 
started early after asAH onset, but at the same time 
were associated with an increased incidence of treat-
able hyperglycemia and hypokalemia. Administration 
of isotonic fluid can prevent volume contraction but 
not hyponatremia. use of slightly hypertonic sodium 
chloride (1.5% sodium chloride) at rates above main-
tenance requirements usually is efficacious for asAH-
induced hyponatremia. data suggest that 3% saline 
may be safe but are too scant to assess its value in the 
management of hyponatremia190. 
Concerning the management of hyponatremia, it 
can be recommended according to current practice and 
general agreements that fluid restriction should not be 
used to treat hyponatremia; early treatment with hy-
drocortisone or fludrocortisone may be used to limit 
natriuresis and hyponatremia; mild hypertonic saline 
solutions can be used to correct hyponatremia; and 
free water intake via intravenous and enteral routes 
should be limited21. furthermore, it should be em-
phasized that when hyponatremia in asAH patients 
is treated promptly and appropriately, the patients’ 
sodium levels return to normal without detrimental 
effects. Thus, it is strongly recommended to anticipate 
hyponatremia in patients with asAH, timely detect 
and appropriately treat it to improve outcome191.
Recommendations for medical treatment of 
hyponatremia after aSAH
•	 fluid restriction should not be used to treat hy-
ponatremia21 (weak Quality evidence; strong 
Recommendation). 
•	 The	use	of	fludrocortisone	or	hydrocortisone	and	
hypertonic saline solution is reasonable for pre-
venting and correcting hyponatremia22 (moder-
ate Quality evidence; strong Recommendation). 
early treatment with fludrocortisone or hydro-
cortisone may be used to limit natriuresis and hy-
ponatremia21 (moderate Quality evidence; weak 
Recommendation). 
•	 Mild	 hypertonic	 saline	 solutions	 can	 be	 used	 to	
correct hyponatremia21 (Very low Quality evi-
dence; strong Recommendation). 
•	 Extreme	caution	to	avoid	hypovolemia	is	needed	if	
vasopressin-receptor antagonists are used for treat-
ment of hyponatremia21 (weak Quality evidence; 
strong Recommendation). 
•	 Free	 water	 intake	 via intravenous and enteral 
routes should be limited21 (Very low Quality evi-
dence; strong Recommendation).
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sažetak
pRepoRuKe ZA liJečenJe KompliKACiJA u bolesniKA nAKon AneuRiZmAtsKog 
subARAHnoidnog KRVARenJA
predstavljamo smjernice za liječenje komplikacija u bolesnika nakon aneurizmatskog subarahnoidnog krvarenja te-
meljene na dokazima, a prihvaćene od strane Hrvatskoga društva za neurovaskularne poremećaje, Hrvatskoga društva za 
neurologiju uključivo i sekciju za intenzivnu neurologiju, Hrvatskoga društva za neurokirurgiju, Hrvatskoga društva za 
zbrinjavanje otežanog dišnog puta i Hrvatskoga liječničkog zbora. sastoje se od preporuka za zbrinjavanje, praćenje i lije-
čenje bolesnika nakon aneurizmatskog subarahnoidnog krvarenja, temeljenih na dostupnoj literaturi, rezultatima velikih 
međunarodnih kliničkih ispitivanja i kolektivnog iskustva autora.
Ključne riječi: Subarahnoidno krvarenje; Aneurizma; Komplikacije; Terapija lijekovima; Praktična smjernica
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subarachnoid hemorrhage (sAH) is a neurologic 
emergency and a cerebrovascular event with frequent 
devastating effects on the central nervous system, pos-
sible secondary brain injury due to delayed cerebral 
ischemia and common systemic manifestations af-
fecting cardiovascular, renal and pulmonary function. 
sAH is a significant cause of morbidity and mortal-
ity throughout the world, which makes it a relevant 
health problem. it occurs with an incidence of 2 to 
20 cases per 100,000 individuals. it varies from re-
gion to region and the aggregate worldwide incidence 
is about 10 cases per 100,0001. it accounts for 2 to 5 
percent of all new strokes. The prognosis is influenced 
by multiple non-modifiable factors and by factors 
that can be influenced by therapeutic interventions 
and management procedures. Current developments 
in neurocritical care have improved the level of care 
and clinical outcome, however, the lack of high qual-
ity data has led to numerous approaches to manage-
ment and limited guidance on choosing among them. 
Recent international guidelines are available in the 
united states of America from the neurocritical Care 
society2 and American Heart Association/American 
stroke Association3, and in the european union from 
the european stroke organisation4. due to some dif-
ferences in the epidemiology and technical diagnostic 
and management specificities, it turned out pragmati-
cally to publish recommendations from the Croatian 
standpoint. 
Definitions of Classes and Levels of Evidence 
Used in Recommendations
Class i Conditions for which there is evidence for 
and/or general agreement that the proce-
dure or treatment is useful and effective. 
Class ii Conditions for which there is conflicting 
evidence and/or a divergence of opinion 
about the usefulness/efficacy of a proce-
dure or treatment. 
Class iia The weight of evidence or opinion is in 
favor of the procedure or treatment.
Class iib usefulness/efficacy is less well established 
by evidence or opinion. 
Class iii Conditions for which there is evidence 
and/or general agreement that the pro-
cedure or treatment is not useful/effective 
and in some cases may be harmful. 
Therapeutic recommendations 
level of  data derived from multiple randomized
evidence A clinical trials or meta-analyses.
level of  data derived from a single randomized
evidence b trial or nonrandomized studies. 
level of 
evidence C Consensus opinion of experts, case stud-
ies, or standard of care. 
Diagnostic recommendations
level of  data derived from multiple prospective
evidence A cohort studies using a reference standard 
applied by a masked evaluator. 
level of  data derived from a single grade A study,
evidence b or ≥1 case-control studies, or studies us-
ing a reference standard applied by an 
unmasked evaluator. 
level of  
evidence C Consensus opinion of experts.
Risk Factors
Risk factors can be divided into risk factors for 
sAH (non-modifiable risk factors: sex, age, size of an-
eurysm and family history, and modifiable: cigarette 
smoking, hypertension and excessive alcohol intake), 
risk factors for aneurysm formation (female sex, cur-
rent cigarette smoking, hypertension, age at diagno-
sis and family history) and risk factors for aneurysm 
growth (current cigarette smoking).
The incidence in women is 1.24 times higher 
than in men5. evidence of a sex-age effect on sAH 
incidence has emerged from pooled study data, with 
a higher incidence reported in younger men (25-45 
years of age), women between 55 and 85 years of age, 
and men >85 years of age5,6. 
An important but non-modifiable risk factor is fa-
milial predisposition to sAH. between 5% and 20% 
of patients with sAH have a positive family history7. 
first-degree relatives of patients with sAH have a 3- 
to 7-fold increased risk of being struck by the same 
disease8-13. in second-degree relatives, the incidence of 
sAH is similar to that found in the general popula-
tion8. Also, many studies show that around 10% of 
patients with sAH have a family history. The chance 
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of finding an aneurysm at screening is around 10% if 
two or more first-degree relatives are affected8-10. two 
large observational studies of familial aneurysms sug-
gest that screening these patients may also be cost-
effective in preventing aneurysmal sAH (asAH) and 
improving the quality of life14,15.
The occurrence of sAH is also associated with 
specific heritable disorders of connective tissue, but 
these patients account for only a minority of all pa-
tients with sAH. even though autosomal dominant 
polycystic kidney disease (AdpKd) is the most com-
mon heritable disorder associated with sAH, it is 
found in only 2% of all patients with sAH16,17. other 
genetically determined disorders that have been asso-
ciated with sAH are ehlers-danlos disease type iV 
and neurofibromatosis type 1, but these associations 
are weaker than between AdpKd and aneurysms 
and these syndromes are seldom found in patients 
with sAH17-19. 
The major identified modifiable risk factors include 
cigarette smoking, hypertension, alcohol abuse and 
use of sympathomimetic drugs (e.g., cocaine)3. Ciga-
rette smoking is an independent and the most impor-
tant risk factor for sAH, aneurysm formation, growth 
and rupture4. in developed countries of western hemi-
sphere, the prevalence of smoking in sAH patients is 
45%-75% (in general adult population 20%-35%), in 
addition 40% of all sAH patients can be attributed to 
cigarette smoking20-25. The prevalence of hypertension 
among sAH patients (20%-45%) is somewhat higher 
than in the general population. even though the data 
regarding the relationship between hypertension and 
sAH are somewhat conflicting, hypertension can be 
considered to be an important risk factor for sAH and 
possibly for aneurysm formation and fatal aneurysm 
rupture20-24. Alcohol abuse and particularly sudden 
intake of high quantities is a risk factor for aneurysm 
rupture and should be desisted20-25. However, despite 
marked improvements in the treatment of hyperten-
sion and hyperlipidemia and the decrease in the rates 
of smoking over time, the incidence of sAH has not 
changed appreciably in the last 30 years26. further on, 
greater vegetable consumption is associated with a 
lower risk of stroke and sAH27. Higher coffee and tea 
consumption28 and higher magnesium consumption29 
were associated with a reduced risk of stroke overall, 
but did not change the risk of sAH. 
The risk of growth and aneurysm rupture remains 
disputable, quite depending on the size and location 
of the aneurysm30,31. According to an international 
study of unruptured intracranial aneurysms30, in pa-
tients with no history of sAH, the five-year cumula-
tive rate of rupture of aneurysms located in the in-
ternal carotid artery, anterior communicating artery, 
anterior cerebral artery, or middle cerebral artery is 
zero for aneurysms under 7 mm, 2.6% for 7 to 12 mm, 
14.5% for 13 to 24 mm, and 40% for 25 mm or more. 
This rate is in contrast to rupture rates of 2.5%, 14.5%, 
18.4% and 50%, respectively, for the same sizes of 
aneurysms in the posterior circulating and posterior 
communicating artery32. in addition, when followed 
up on magnetic resonance imaging (mRi), aneurysms 
≥8 mm tended to grow more over time33, which im-
plies a higher risk of rupture. several characteristics 
of aneurysm morphology such as a bottleneck shape34 
and the aneurysm size to parent vessel ratio35,36 have 
been associated with rupture status, but how these 
might be applied to individual patients to predict fu-
ture aneurysmal rupture is still unclear. in addition 
to the mentioned international study of unruptured 
intracranial aneurysms30, new findings suggest that 
the risk of first episodes of rupture of aneurysms un-
der 7 mm in anterior cerebral circulation does exist, 
although slightly lower than 1%37.
patients with adequately obliterated aneurysms af-
ter asAH have a low risk of recurrent asAH for at 
least 5 years38, although some coiled aneurysms re-
quire retreatment39. 
Risk factor recommendations
1. High blood pressure is an important risk factor, 
so hypertension treatment may reduce the risk of 
asAH (Class i; level of evidence b).
2. Cigarette smoking and alcohol abuse should be 
ceased in order to reduce the risk of asAH3 (Class 
i; level of evidence b).
3. The risk of aneurysm rupture might be evaluated 
considering its size, location and morphological 
and hemodynamic characteristics, together with 
the patient’s age and health status3 (Class iib; lev-
el of evidence b). 
4. noninvasive screening is reasonable to be consid-
ered when two or more first-degree relatives are af-
fected (Class iib; level of evidence b).
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Clinical Presentation and Diagnosis
Although headache is a common presenting chief 
complaint in the emergency department, and asAH 
accounts for only 1% of all headaches evaluated in the 
emergency department, it should always be suspected 
in patients with a typical presentation, one of the most 
pathognomonic pictures in all of clinical medicine40.
The central feature of classic asAH is sudden on-
set of severe headache, approximately 80% of patients 
describe the pain as “the worst headache of my life”41. 
Any patient’s first or worst headache should suggest 
asAH and prompt ordering of head computed to-
mography (Ct) scan. in more than 20% of patients, 
less severe hemorrhages may cause headache of mod-
erate intensity, neck pain, and nonspecific symptoms. 
Headache is often accompanied with nausea, vomit-
ing, neck stiffness and back pain, photophobia, loss 
of consciousness, seizures or focal neurological deficits 
(including cranial nerve palsies).
despite the classic presentation, asAH is misdi-
agnosed in approximately 12% of cases. The common 
incorrect diagnoses are migraine and tension-type 
headaches. The most common diagnostic error is fail-
ure to obtain a noncontrast head Ct scan42,43.
prodromal events in the form of sentinel or warn-
ing leaks, with minor loss of blood from the aneu-
rysm before a major rupture, are reported to occur 
in 30%-50% of asAH and precede overt asAH by 
2 to 8 weeks44,45. sentinel leaks produce sudden fo-
cal or generalized head pain that may be severe. in 
addition to headaches, sentinel leaks may produce 
nausea, vomiting, photophobia or, less commonly, 
neck pain. These symptoms may be ignored by the 
physician. Therefore, a high index of suspicion is 
necessary because diagnosis of the warning leak or 
sentinel hemorrhage before a catastrophic rupture 
may be lifesaving46. sentinel leaks usually do not 
generate symptoms suggestive of elevated intracra-
nial pressure (iCp) or meningeal irritation and they 
usually do not occur in patients with arteriovenous 
malformations. prodromal presentations occasion-
ally are also caused by the mass effect of an expand-
ing aneurysm and have characteristic features based 
on aneurysm location.
The clinical condition upon admission of a patient 
is most commonly rated with the glasgow Coma 
scale (gCs)47, Hunt and Hess scale (HHs)48 or the 
world federation of neurological surgeons scale 
(wfns)49. obtaining a score with either HHs or 
wfns on admission is recommended, as this is the 
single most useful predictor of long-term outcome3. 
since subarachnoid blood is almost always detect-
able on Ct scans on the first day of asAH, with its 
typical distribution in the subarachnoid space/basal 
cisterns, noncontrast Ct remains the single most im-
portant test for the diagnosis of asAH3. Therefore, if 
asAH is clinically suspected, cranial Ct should be 
performed to confirm the diagnosis4. in the first 24 
hours, the sensitivity of Ct for sAH is 92%-95%50-55. 
with the newer generation of Ct scanners, the sensi-
tivity reaches 97%-100% within the first 6 h and 87% 
at 6 h or more after symptom onset53. The sensitivity to 
detect blood on head Ct declines to 57%-85% on days 
5 and 6 and declines to 50% after 1 week52,56. fisher 
scale is a radiological scale based on the amount and 
distribution of blood on Ct. The score corresponds to 
the likelihood of delayed cerebral ischemia (dCi) to 
occur57. 
Advances in mRi of the brain58-60 can often al-
low the diagnosis of asAH to be made when head 
Ct scan is negative and there is clinical suspicion of 
asAH, possibly avoiding the need of lumbar punc-
ture.
However, in case of history or clinically suspect-
ed sAH, despite negative/inconspicuous Ct and/or 
mRi scans, lumbar puncture should be performed3,4. 
The usefulness of mRi and mR angiography 
(mRA) in the acute setting is often limited by logis-
tics, the need of acute resuscitation and critical care 
management of the patient and motion artifacts3. 
Computed tomographic angiography (CtA) is more 
readily obtainable and faster than mRA. This imag-
ing modality carries a sensitivity of 77%-100% for 
all aneurysms and 95%-100% for aneurysms ≥5 mm. 
However, aneurysms <3 mm in size continue to be 
unreliably demonstrated on CtA61,62. in cases of per-
imesencephalic sAH, the role of CtA is still contro-
versial; it remains unclear whether a negative CtA 
result is sufficient to rule out aneurysmal hemorrhage 
and that cerebral angiography is not required63,64. 
digital subtraction angiography (dsA) was in-
dicated if there was a diffuse aneurysmal pattern of 
asAH, and repeat delayed dsA was required if the 
initial dsA findings were negative, which led to the 
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detection of a small aneurysm in 14% of cases. so, 
despite the presence of less invasive methods (mRA 
and CtA), cerebral panangiography (dsA) continues 
to be the gold standard for detection, demonstration 
and localization of ruptured aneurysms4. The rate of 
complications associated with this invasive diagnostic 
procedure is below 0.5% in experienced centers65.
Clinical presentation and diagnosis recommendations
1. asAH is a medical emergency typically presented 
with sudden onset of severe headache, however, 
frequently misdiagnosed3 (Class i; level of evi-
dence b).
2. As the most useful indicator of outcome after 
asAH, the simple validated scales (e.g., Hunt and 
Hess, world federation of neurological surgeons) 
should be used for rapid determination of the ini-
tial clinical severity of asAH3 (Class i; level of 
evidence b).
3. The risk of early aneurysm rebleeding is high, and 
rebleeding is associated with very poor outcomes. 
Therefore, urgent evaluation and treatment of 
patients with suspected asAH is recommended3 
(Class i; level of evidence b).
4. Acute diagnostic workup should include noncon-
trast head Ct, which, if nondiagnostic, should be 
followed by lumbar puncture3 (Class I; Level of Evi-
dence B). 
5. Ct/CtA and multisequential mRi/mRA are 
equally suitable for the diagnosis of sAH within 
24 h and may confirm the underlying cause4 (Class 
ii; level of evidence b).
6. CtA may be considered in the workup of asAH. 
if an aneurysm is detected by CtA, this study may 
help guide the decision on the type of aneurysm 
repair, but if CtA is inconclusive, dsA is still rec-
ommended (except possibly in the instance of clas-
sic perimesencephalic asAH)3 (Class iib; level of 
evidence C).
7. mRi (fluid-attenuated inversion recovery, proton 
density, diffusion-weighted imaging, and gradient 
echo sequences) may be reasonable for the diagno-
sis of asAH in patients with a nondiagnostic Ct 
scan, although a negative result does not obviate 
the need of cerebrospinal fluid analysis3 (Class iib; 
level of evidence C).
8. dsA is indicated for detection of aneurysm in pa-
tients with asAH (except when the aneurysm was 
previously diagnosed by noninvasive angiogram) 
and for planning treatment (to determine whether 
the aneurysm is suitable to coiling or to expedite 
microsurgery)3 (Class i; level of evidence b).
9. if no aneurysm was found, in patients with non-
perimesencephalic sAH (with typical pattern of 
sAH) CtA or dsA should be repeated not earlier 
than 3 weeks after the initial bleeding, if there are 
no other therapeutic indications to perform imaging 
studies earlier4 (Class ii; level of evidence C).
Treatment
All patients with asAH should be evaluated and 
treated on an emergency basis with maintenance of 
airway and cardiovascular function. 
After initial stabilization, patients should be trans-
ferred to centers with neurovascular expertise and pref-
erably with a dedicated neurological critical care unit to 
optimize care66,67. The patients diagnosed with asAH 
should be treated at high volume centers (>35 cases per 
year) with appropriate specialty neurointensive care 
units (niCus), neurointensivists, vascular neurosur-
geons and interventional neuroradiologists68-70. 
once in the (neuro)critical care setting, the main 
goal of treatment is primarily aneurysm repair togeth-
er with the prevention of rebleeding, prevention and 
management of vasospasm, and treatment of other 
medical and neurological complications. 
staff in this unit should have ample experience in 
assessing swallowing function to prevent pneumonia, 
a frequent complication after sAH and an indepen-
dent risk factor for poor outcome71. 
electrocardiography (eCg), level of conscious-
ness (gCs), pupils, focal deficits and temperature 
should be monitored frequently for at least the first 7 
days after asAH, or longer as required depending on 
the patient’s clinical condition4. 
elevated iCp is often associated with asAH. it 
can be caused by hydrocephalus, space-occupying in-
tracerebral hemorrhage (iCH), and global and focal 
cerebral edema. Hydrocephalus occurs in 20%-30% 
of patients after sAH72-74. The treatment of choice is 
insertion of an extraventricular drain (eVd)3, which 
may result in prompt clinical response such as im-
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provement of consciousness75. The risk of infection 
ranges from 2.2% to 21.9%, depending on the num-
ber of manipulations and sterile techniques used. if 
there is no improvement after 36-48 h and the iCp 
is low, a poor neurological state is likely due to pri-
mary brain injury related to the acute effects of hem-
orrhage. weaning of the eVd should begin after iCp 
has been controlled for 48 h, either by trials of inter-
mittent clamping or raising the eVd level with iCp 
monitoring. Craniotomy and surgical decompression 
is reasonable in space-occupying intraparenchymal 
hemorrhages. decompressive craniectomy can be 
beneficial in patients with life-threatening cerebral 
edema with and without intracerebral hemorrhage, 
due to infarction or recurrent hemorrhage, and should 
be performed rapidly to avoid herniation76.
in the intensive care unit, blood pressure (bp) is 
monitored continuously via an arterial line. treatment 
of hypertension remains controversial. data from ob-
servational studies suggest that aggressive treatment 
of bp may decrease the risk of rebleeding but at the 
cost of an increased risk of secondary ischemia77. it 
seems reasonable, but without good evidence not to 
treat hypertension unless the bp is extreme. limits 
for extreme bp should be set on individual basis, tak-
ing into account age of the patient, pre-sAH bp and 
cardiac history. systolic bp should be kept below 160 
mm Hg (for example, by means of esmolol or labe-
tolol), only until coiling or clipping of ruptured aneu-
rysm, to reduce the risk for rebleeding3,4. 
Regarding fluids and electrolytes, intravenous line 
is mandatory. A calculated fluid balance every 6 h dur-
ing the initial week is advised in all patients, as well as 
urinary catheter. normovolemia should be aimed4. 
Headache pain should be treated initially with 
paracetamol (500 mg every 3-4 h). salicylates are 
best avoided because their antihemostatic effect is un-
wanted in patients who may have to undergo external 
ventricular drainage and interferes with the possibly 
pending neurosurgical interventions. for severe pain, 
use of codeine and tramadol are reasonable, while 
synthetic opiate like piritramide might be considered 
only as the last resort4. 
to avoid situations that increase iCp, the patient 
should be kept in bed and the application of antiemet-
ic drugs, laxatives and analgesics should be considered 
before occlusion of the aneurysm4.
Hyperglycemia develops in one-third of sAH pa-
tients. Hyperglycemia is associated with poor clinical 
condition on admission, and is independently associ-
ated with poor outcome78-81.
Regarding thromboprophylaxis, in a placebo-con-
trolled trial of enoxaparin (a low-molecular-weight 
heparin, lmwH) administered subcutaneously 40 
mg once a day after surgical aneurysm occlusion, in-
tracranial bleeding complications occurred somewhat 
more often in the enoxaparin group, while there was 
no overall influence on outcome or occurrence of 
post-sAH cerebral infarction82,83. enoxaparin also 
increased the incidence of postoperative intracranial 
hemorrhage when initiated preoperatively for deep 
venous thrombosis prophylaxis in patients with brain 
tumors84. because of this increased risk of intracra-
nial bleeding from thromboprophylaxis by means of 
lmwH, the use of stockings or pneumatic devices 
seems more appropriate in sAH patients. A study 
with nonrandomized controls has suggested that deep 
vein thrombosis can be successfully prevented by the 
use of pneumatic devices85. A Cochrane review on the 
use of graduated compression stockings or intermit-
tent pneumatic compression in patients with stroke 
did not find support for the use of either method86. 
in a randomized trial in patients with iCH, the com-
bination of stockings and intermittent pneumatic 
compression resulted in a smaller risk of deep venous 
thrombosis than prevention by stockings alone87. This 
combination may be the preferred strategy because 
there is no reason to suppose that this effect would 
be any different in patients with sAH, but it needs 
further study.
seizures at onset occur in around 7% of patients, 
but their impact on prognosis is uncertain88. Another 
10% develop seizures in the first few weeks89, and con-
vulsive status epilepticus occurs in 0.2%90. in patients 
who are comatose, nonconvulsive status epilepticus 
has been detected in 8% of patients91, but the propor-
tion in this study might be an overestimation due to 
selection of electroencephalography (eeg) by indi-
cation. whether continuous eeg monitoring should 
be performed in all sAH patients or in the subset of 
comatose patients is an unresolved issue. An observa-
tional study performed in 3,552 patients participating 
in 4 prospective, randomized, double-blind, placebo-
controlled trials suggested that the outcome was worse 
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in 65% of patients receiving prophylactic antiepileptic 
drugs than in the other 35% of patients who did not 
receive prophylactic antiepileptic medication92. given 
the lack of evidence in favor of prophylactic treatment 
with antiepileptic drugs and the possible disadvan-
tage of serious adverse drug reactions, current advice 
should be not to start antiepileptic drugs as prophy-
lactic treatment.
The use of hydrocortisone in patients with sAH 
does not improve clinical outcome but it doubles the 
risk of hyperglycemia4.
patients in a good clinical condition in whom the 
aneurysm has been secured can be transferred to a 
regular care bed in the stroke unit4.
Treatment recommendations
1. to avoid situations that increase iCp, the patient 
should be kept in bed and the application of an-
tiemetic drugs, laxatives and analgesics should 
be considered before occlusion of the aneurysm4 
(Class iia; level of evidence C).
2. Hyperglycemia over 10 mmol/l should be treated4 
(Class iia; level of evidence C).
3. increased temperature should be treated medically 
and physically4 (Class iia; level of evidence C).
4. until coiling or clipping, systolic bp should be kept 
below 160 mm Hg3 (Class iia; level of evidence 
C). if systolic pressure remains high despite these 
treatments, further lowering of bp should be con-
sidered4 (Class iii; level of evidence C). if bp is 
lowered, the mean arterial pressure should be kept 
at least above 90 mm Hg4 (Class iia; level of evi-
dence C).
5. patients with sAH may be given thromboprophy-
laxis with pneumatic devices and/or compression 
stockings before occlusion of the aneurysm. in 
case deep vein thrombosis prevention is indicated, 
lmwH should be applied not earlier than 12 h 
after surgical occlusion of the aneurysm and im-
mediately after coiling4 (Class ii; level of evidence 
b).
6. Antiepileptic treatment should be administered in 
patients with clinically apparent seizures4 (Class 
iia; level of evidence C). There is no evidence 
that supports the prophylactic use of antiepileptic 
drugs4 (Class iii; level of evidence C).
7. There is no proof that steroids are effective in pa-
tients with sAH4 (Class iii; level of evidence C). 
Aneurysm Repair
Currently, the two main therapeutic options for 
securing a ruptured aneurysm are microvascular neu-
rosurgical clipping and endovascular coiling. Histor-
ically, microsurgical clipping has been the preferred 
method of treatment. Although the timing of sur-
gery has been debated, most neurovascular surgeons 
recommend early operation. evidence from clinical 
trials suggest that patients undergoing early surgery 
have a lower rate of rebleeding and tend to fare better 
than those treated later93. securing the ruptured an-
eurysm will also facilitate the treatment of compli-
cations such as cerebral vasospasm. Although many 
neurovascular surgeons use mild hypothermia dur-
ing microsurgical clipping of aneurysms, it has not 
proved to be beneficial in patients with lower grades 
of sAH94. 
in the early beginnings of cerebral aneurysm treat-
ment, surgery was the only approach in aneurysm re-
pair. since the development of aneurysm clips, the risk 
of rebleeding has significantly decreased. with the 
establishment of microsurgery, surgical approaches 
have become smaller and less traumatizing. further-
more, intraoperative indocyanine green angiography 
and doppler sonography lead to extra intraoperative 
quality control. 
After the invention of detectable platinum coils by 
g. guglielmi in 1990, an alternative to surgical clip-
ping has been developed95. endovascular treatment 
of aneurysms has been available as an alternative to 
surgical therapy for more than 20 years now. Coils 
are made of platinum and are attached to a delivery 
wire. once proper position within the aneurysm is 
achieved, coils are detached from the wire. multiple 
coils of various length and diameter are often packed 
into the aneurysm to exclude it from the circulation. 
The international subarachnoid Aneurysm trial 
(isAt) was a landmark study that validated the tech-
nique of endovascular coiling96,97. 
with advancements in both microsurgical and en-
dovascular approaches, algorithms to determine the 
proper patient population and aneurysmal character-
istics for each treatment are continually undergoing 
refinement.
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Timing of aneurysm repair
up to 15% of patients rebleed during the first few 
hours after the initial hemorrhage, that is, during 
transportation or before the treatment team is able 
to occlude the aneurysm. patients surviving the first 
day after the initial asAH have a cumulative risk of 
35%-40% to suffer rebleeding of the aneurysm with a 
mortality rate of about 40%. After 4 weeks, the risk of 
rebleeding decreases to about 3%/year98. The primary 
goal of asAH treatment is occlusion of the ruptured 
aneurysm, i.e. to close the bleeding source prevent-
ing rebleeding. As mentioned, two major treatment 
options are available: neurosurgical clipping and en-
dovascular coiling. A meta-analysis of 11 out of 268 
studies with a total of 1,814 patients revealed in a 
comparative evaluation of early versus late surgical 
clipping of ruptured aneurysms that early treatment 
(within 72 h after sAH) of patients with a good clini-
cal/neurological condition on admission (wfns 1-3) 
led to a significantly better outcome. A similar trend, 
without statistical significance, could be detected in 
patients with worse wfns grades 4-599. even ear-
lier treatment (within 12 h) of sAH patients with 
wfns grades iV and V did not increase the number 
of dependent survivors100. Although there are no good 
evidence-based data, a general long-lasting consensus 
exists that ruptured aneurysms of patients with good 
and moderate clinical sAH grades (wfns 1-4; Hunt 
and Hess grade i–iV) should be treated in the early 
phase after the initial bleeding (<72 h after sAH). in 
patients presenting with multiple intracranial aneu-
rysms, i.e. with one ruptured aneurysm causing sAH 
and several unruptured incidental aneurysms, the 
ruptured aneurysm is primarily treated. subsequent 
treatment of the unruptured incidental aneurysms de-
pends on the clinical course after sAH, outcome, age, 
size, location and configuration of the aneurysm.
Surgical clipping and endovascular coiling
The decision should be made by a team of neuro-
logical, neurosurgical and interventional cerebrovas-
cular experts. isAt was the only multicenter random-
ized trial comparing microsurgical and endovascular 
repair (clipping and coiling but without balloon or 
stent techniques)97. The isAt study followed the ‘un-
certainty principle’. The main inclusion criterion of 
isAt was that a ruptured aneurysm seemed equally 
accessible and treatable by either surgical clipping or 
endovascular coiling (‘clinical equipoise’). This inclu-
sion criterion was met by 22.4% of patients (2,143 of 
9,559 patients) treated during the study period at the 
study centers. The remaining 77.6% of patients suf-
fered from aneurysms which were preferably treated 
by either coiling or clipping. Those patients were not 
randomized and were excluded from the study. be-
sides a highly selected patient cohort, isAt was also 
criticized for its high (90%) proportion of patients 
with good clinical grades after sAH (Hunt and Hess 
grades 1-2) and underrepresentation of middle cere-
bral artery aneurysms, which are often anatomically 
more difficult to be coiled than aneurysms in other 
locations. However, for this subpopulation of rup-
tured aneurysms, which were equally coilable or clip-
pable, isAt showed that endovascular coiling had an 
advantage over surgical clipping, with better clinical 
outcome: absolute risk reduction of death and severe 
disability after 1 year was 6.9% in favor of coiling ver-
sus clipping, based on the observation that 23.7% of 
endovascular-treated patients (compared to 30.6% of 
patients after clipping) stayed severely disabled or died 
after 1 year97. The 9-year follow-up of isAt also re-
vealed a reduction in the relative 5-year mortality risk 
in favor of coiling. no difference could be observed in 
the amount of independent sAH survivors between 
the clip (82%) and coil (83%) group. both early and 
follow-up isAt analysis showed that patients treated 
with coiling had a higher rebleeding risk, which was 
comparable to the risk of suffering sAH from a new 
aneurysm97,101. The postoperative risk of rebleeding 
appears to be associated with the degree of insuffi-
cient aneurysm occlusion. Another follow-up study 
of the patients treated in the isAt was performed to 
compare the frequency and consequences of aneurysm 
recurrence. Retreatment was performed in 17.4% of 
patients after primary endovascular coiling and in 
3.8% of patients after neurosurgical clipping. late 
retreatment was 6.9 times more likely after coiling. 
younger age, larger lumen size, and incomplete oc-
clusion were the risk factors for late retreatment after 
coiling102. A post hoc modeling study with mortality as 
outcome parameter only after coiling and clipping for 
patients from the isAt emphasized that no advan-
tage of coil embolization over clip ligation could be 
assumed for patients younger than 40 years. for these 
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patients, clipping might even be a better treatment 
option in terms of life expectancy103,104. because of the 
highly selected aneurysm subpopulation in isAt, its 
results cannot be generalized. 
Although in endovascular coiling, the complete 
obliteration rate can be increased by the addition of 
a high-porosity stent, this has been associated with 
an increased risk of complications, especially in pa-
tients with sAH, in large part because of the need 
of periprocedural dual-antiplatelet therapy to prevent 
arterial thromboembolism105. whether low-porosity 
flow-diverting stents with or without coils represent 
a better option for many or most of those presenting 
with sAH from saccular aneurysms, remains to be 
studied, but these stents make more conceptual sense 
for use in the patient with a dissecting aneurysm, in 
whom vessel sacrifice is not an option and microsurgi-
cal solutions carry a higher risk. 
Recent advances in technique including the balloon 
remodeling technique that holds the coils in the an-
eurysm cavity, liquid polymer coils and embolic agents 
make treatment of broad neck aneurysm feasible. 
Recent studies, which consider increasing endo-
vascular treatment during the last years, could not 
detect any difference in mortality and morbidity be-
tween coiling and clipping104. The main concern about 
endovascular therapy is an increased rate of rebleeding 
after several years due to coil compaction and aneu-
rysm regrowth at the residual neck.
given this delicate balance between safety and du-
rability, there have been multiple efforts to identify 
subgroups of patients who might be best treated with 
endovascular or microsurgical techniques. The qual-
ity of data is modest. summarizing current studies, 
ruptured aneurysms are complex lesions. 
The primary goal of treatment should be complete 
occlusion of the aneurysm sack to reduce postproce-
dural rerupture and bleeding. in case of aneurysms 
which can be treated equally with clipping or coiling, 
without stent or balloon, endovascular therapy is pre-
ferred. However, indications and treatments should 
be discussed in an interdisciplinary dialogue. in case 
of an accompanying space occupying intracerebral he-
matoma, surgical treatment and clipping is preferred.
As a rough guidance, aneurysms with a wide neck, 
branching vessels out of the aneurysm sack, middle 
cerebral artery aneurysms or patients with intracere-
bral hematoma should preferably be treated by clip-
ping, while aneurysms of the basilar artery or elderly 
patients (patients >70 years, small aneurysm neck, 
posterior circulation) should be coiled. Any decision 
concerning treatment should be interdisciplinary and 
based on the experience and treatment results of the 
neurosurgeon and endovascular radiologist together 
with cerebrovascular neurologist, and should be adapt-
ed to the individual aspects including parameters such 
as age, general state of health, location, configuration 
and size of the aneurysm, as well as the request of 
the patient. patients with asAH should be treated in 
centers that offer high-quality treatment with both 
modalities because the skills of the treating interven-
tionalist or neurosurgeon, as well as the institution, 
may have great impact on outcome.
Treatment of ruptured aneurysm – surgical and 
endovascular methods: recommendations
1. Ruptured aneurysm should be treated as early as 
logistically and technically possible to reduce the 
risk of rebleeding after asAH; if possible, it should 
be aimed to intervene at least within 72 h after on-
set of first symptoms4 (Class i; level of evidence 
b). The decision should not depend on grading4 
(Class iib; level of evidence C). 
2. Complete obliteration of the aneurysm is recom-
mended3 (Class i; level of evidence b). 
3. The decision for the best mode of aneurysm treat-
ment, as judged by experienced cerebrovascular 
neurologists, cerebrovascular surgeons and endo-
vascular specialists, should be multidisciplinary 
and based on characteristics of the patient and the 
aneurysm, and the patient should be informed and 
included in the process of decision making3,4 (Class 
i; level of evidence C). 
4. in general, the decision on whether to clip or coil 
depends on several factors related to 3 major com-
ponents: (1) patient: age, comorbidity, presence 
of iCH, sAH grade, aneurysm size, location and 
configuration, as well as the status of collaterals; 
(2) procedure: competence, technical skills and 
availability; and (3) logistics: the grade of inter-
disciplinarity4 (Class iib, level of evidence b).
5. factors in favor of operative intervention (clip-
ping) in patients with asAH are: younger age, 
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presence of space occupying iCH and aneurysm-
specific factors such as location (middle cerebral 
artery and pericallosal aneurysm), wide aneurysm 
neck and arterial branches exiting directly out of 
the aneurysmal sack (Class iib, level of evidence 
b), or other unfavorable vascular and aneurysmal 
configuration for coiling4. 
6. factors in favor of endovascular intervention (coil-
ing) in patients with asAH are: age above 70 
years, patients presenting with poor-grade (world 
federation of neurological surgeons classification 
iV/V) asAH, space occupying iCH not present, 
and aneurysm-specific factors such as posterior 
location, small aneurysm neck, unilobar shape4 
(Class iib, level of evidence b).
7. for patients with ruptured aneurysms judged to be 
technically amenable to both endovascular coiling 
and neurosurgical clipping, endovascular coiling 
should be considered3 (Class i; level of evidence 
b).
8. in the absence of a compelling contraindication, 
patients who undergo coiling or clipping of a rup-
tured aneurysm should have delayed follow-up 
vascular imaging (timing and modality to be in-
dividualized), and strong consideration should be 
given to retreatment, either by repeat coiling or 
microsurgical clipping, if there is a clinically sig-
nificant (e.g., growing) remnant3 (Class i; level of 
evidence b). 
9. stenting of a ruptured aneurysm is associated with 
increased morbidity and mortality, and should 
only be considered when less risky options have 
been excluded3 (Class iii; level of evidence C).
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sažetak
opće pRepoRuKe ZA liJečenJe AneuRiZmAtsKog subARAHnoidnog KRVARenJA
subarahnoidno krvarenje je hitno neurološko stanje s visokom stopom smrtnosti i komplikacija. preporuke su te-
meljene na dostupnoj literaturi, rezultatima velikih međunarodnih kliničkih ispitivanja i kolektivnom iskustvu autora, a 
prihvaćene od strane Hrvatskoga društva za neurovaskularne poremećaje, Hrvatskoga društva za neurologiju uključivo i 
sekciju za intenzivnu neurologiju, Hrvatskoga društva za neurokirurgiju, Hrvatskoga društva za zbrinjavanje otežanog 
dišnog puta i Hrvatskoga liječničkog zbora. Cilj ovih preporuka je pomoć liječnicima u donošenju odgovarajućih odluka u 
dijagnostici i liječenju bolesnika sa subarahnoidnim krvarenjem. 
Ključne riječi: Subarahnoidno krvarenje – dijagnoza; Aneurizma – dijagnoza; Subarahnoidno krvarenje – liječenje; Aneu-
rizma – liječenje; Praktična smjernica
